Use these links to rapidly review the document
TABLE OF CONTENTS
Table of Contents
As filed with the Securities and Exchange Commission on November 6, 2017
Registration Statement No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-1
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
FIBROCELL SCIENCE, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
(State or other jurisdiction of
incorporation or organization)
|
|
2834
(Primary Standard Industrial
Classification Code Number)
|
|
87-0458888
(I.R.S. Employer
Identification Number)
|
405 Eagleview Boulevard
Exton, Pennsylvania 19341
(484) 713-6000
(Address, including zip code, and telephone number, including
area code, of registrant's principal executive offices)
John M. Maslowski
President and Chief Executive Officer
Fibrocell Science, Inc.
405 Eagleview Boulevard
Exton, Pennsylvania 19341
(484) 713-6000
(Name, address, including zip code, and telephone number, including area code, of agent for service)
|
|
|
Copies to:
|
Steven J. Abrams
Hogan Lovells US LLP
1735 Market Street, 23rd Floor
Philadelphia, PA 19103
(267) 675-4600
|
|
Steven M. Skolnick, Esq.
Lowenstein Sandler LLP
1251 Avenue of the Americas
New York, New York 10020
(212) 262-6700
|
Approximate date of commencement of proposed sale to public:
As soon as practicable after this Registration Statement is declared effective.
If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of
1933, check the following box.
o
If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list
the Securities Act registration statement number of the earlier effective registration statement for the same offering.
o
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement for the same offering.
o
If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement for the same offering.
o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an
emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
|
|
|
|
|
|
|
Large accelerated filer
o
|
|
Accelerated filer
o
|
|
Non-accelerated filer
o
(Do not check if a
smaller reporting company)
|
|
Smaller reporting company
ý
Emerging growth company
o
|
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.
o
|
|
|
|
|
|
|
|
|
|
|
Title of Each Class of Securities
To Be Registered
|
|
Proposed Maximum
Aggregate Offering
Price(1)
|
|
Amount of
Registration Fee(2)
|
|
Common stock, $0.001 par value per share
|
|
$23,000,000
|
|
$2,863.50
|
|
Underwriter's warrants to purchase common stock(3)
|
|
|
|
|
|
Common stock issuable upon exercise of the underwriter's warrants(4)
|
|
$1,150,000
|
|
$143.18
|
|
Total
|
|
$24,150,000
|
|
$3,006.68
|
|
-
(1)
-
Estimated
solely for purposes of computing the amount of the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended. Includes
shares subject to the underwriter's option to purchase additional shares.
-
(2)
-
Calculated
pursuant to Rule 457(o) based on an estimate of the proposed maximum aggregate offering price of the securities registered hereunder.
-
(3)
-
No
additional registration fee is payable pursuant to Rule 457(g) under the Securities Act.
-
(4)
-
Represents
warrants to purchase a number of shares of common stock equal to 4% of the number of shares of common stock that are being offered in this offering at an
exercise price equal to 125% of the offering price.
The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall
file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as
amended, or until the Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may
determine.
Table of Contents
The information contained in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the registration statement
filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any
jurisdiction where the offer or sale is not permitted.
SUBJECT TO COMPLETION, DATED NOVEMBER 6, 2017
PRELIMINARY PROSPECTUS
Shares
Fibrocell Science, Inc.
Common Stock
We are offering shares of our common stock.
Our
common stock is listed on the Nasdaq Capital Market under the symbol "FCSC." The last reported sale price for our common stock on the Nasdaq Capital Market on November 3, 2017
was $2.05 per share. The actual offering price per share will be as determined between us and the underwriter at the time of pricing, and may be at a discount to the current market price.
You
should rely only on the information contained herein or incorporated by reference in this prospectus. We have not authorized any other person to provide you with different
information.
Investing in our common stock involves a high degree of risk. See "Risk Factors" beginning on page 8 of this prospectus and under similar
headings in the documents incorporated by reference into this prospectus.
|
|
|
|
|
|
|
|
|
|
|
|
|
Per Share
|
|
Total
|
|
Public offering price
|
|
$
|
|
$
|
|
Underwriting discounts and commissions(1)
|
|
$
|
|
$
|
|
Proceeds, before expenses, to us
|
|
$
|
|
$
|
|
-
(1)
-
See
the section titled "Underwriting" for a description of the compensation payable to the underwriter.
We
have granted the underwriter the option to purchase up to an additional shares of common stock to cover over-allotments, if any, at the public offering
price less the
underwriting discounts and commissions. The underwriter may exercise its option at any time within 30 days from the date of this prospectus. If the underwriter exercises the option in full, the
total underwriting discounts and commissions payable by us will be $ , and the total proceeds to us, before expenses, will be
$ .
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this
prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
The
underwriter expects to deliver the shares of common stock to purchasers
on , 2017.
Sole Book-Running Manager
H.C. Wainwright & Co.
The date of this prospectus is , 2017.
Table of Contents
TABLE OF CONTENTS
You
should read this prospectus, including the information incorporated by reference herein, and any related free writing prospectus that we have authorized for use in connection with
this offering.
You
should rely only on the information that we have included or incorporated by reference in this prospectus and any related free writing prospectus that we may authorize to be provided
to you. We have not authorized any underwriter, dealer or other person to give any information or to make any representation other than those contained or incorporated by reference in this prospectus
or any related free writing prospectus that we may authorize to be provided to you. You must not rely upon any information or representation not contained or incorporated by reference in this
prospectus or any related free writing prospectus. This prospectus and any related free writing prospectus do not constitute an offer to sell or the solicitation of an offer to buy any securities
other than the registered securities to which they relate, nor do this prospectus or any related free writing prospectus constitute an offer to sell or the solicitation of an offer to buy securities
in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction.
You
should not assume that the information contained in this prospectus or any related free writing prospectus is accurate on any date subsequent to the date set forth on the front of
the document or that any information we have incorporated by reference herein or therein is correct on any date subsequent to the date of the document incorporated by reference, even though this
prospectus or any related free writing prospectus is delivered, or securities are sold, on a later date.
This
prospectus contains or incorporates by reference summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents
for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed or have been incorporated by
reference as
exhibits to the registration statement of which this prospectus forms a part, and you may obtain copies of those documents as described in this prospectus under the headings "Incorporation by
Reference" and "Where You Can Find More Information."
i
Table of Contents
PROSPECTUS SUMMARY
This summary highlights information contained in other parts of this prospectus and in the documents we incorporate by
reference. Because it is only a summary, it does not contain all of the information that you should consider before investing in shares of our common stock and it is qualified in its entirety by, and
should be read in conjunction with, the more detailed information appearing elsewhere in this prospectus, any applicable free writing prospectus and the documents incorporated by reference herein and
therein. You should read all such documents carefully, especially the risk factors and our consolidated financial statements and the related notes included or incorporated by reference herein or
therein, before deciding to buy shares of our common stock. Unless the context requires otherwise, references in this prospectus to "Fibrocell," "we," "us" and "our" refer to Fibrocell
Science, Inc. and its subsidiaries.
Company Overview
We are an autologous cell and gene therapy company focused on translating personalized biologics into medical breakthroughs for diseases
affecting the skin and connective tissue. Our distinctive approach to personalized biologics is based on our proprietary autologous fibroblast technology. Fibroblasts are the most common cell in skin
and connective tissue and are responsible for synthesizing extracellular matrix proteins, including collagen and other growth factors, which provide structure and support. Because fibroblasts
naturally reside in the localized environment of the skin and connective tissue, they represent an ideal delivery vehicle for proteins targeted to these areas. We target the underlying cause of
disease by using fibroblast cells from a patient's skin and genetically modifying them to create localized therapies that are compatible with the unique biology of the patient, or autologous.
We
are focused on discovering and developing localized therapies for diseases affecting the skin and connective tissue, where there are high unmet needs, to improve the lives of patients
and their families. In that regard, we commit significant resources to our research and development programs. Currently, all of our research and development operations and focus are on gaining
regulatory approvals to commercialize our product candidates in the United States; however, we may seek to expand into international markets in the future.
Our
current pipeline consists of the following product candidates which we are developing in collaboration with Intrexon Corporation, or Intrexon:
Our
most advanced product candidate, FCX-007, is currently in a Phase 1/2 trial for the treatment of recessive dystrophic epidermolysis bullosa, or RDEB. We are also in pre-clinical
development of
1
Table of Contents
FCX-013,
our product candidate for the treatment of moderate to severe localized scleroderma. In addition, we have a third program in the research phase for the treatment of arthritis and related
conditions. See further discussion of our gene-therapy product candidates under the heading "Development Programs" below.
Intrexon Collaborations
We collaborate with Intrexon, a related party, through two distinct exclusive channel collaboration agreements, consisting of the Exclusive
Channel Collaboration Agreement entered into in October 2012, as amended, or the 2012 ECC, and the Exclusive Channel Collaboration Agreement entered into in December 2015, or the 2015 ECC. Pursuant to
these agreements, we engage Intrexon for support services for the research and development of product candidates covered under the respective agreements and reimburse Intrexon for its cost for time
and materials for such work. We are developing FCX-007 and FCX-013 under the 2012 ECC and we are in the research phase for a gene-therapy treatment for arthritis and related conditions under the 2015
ECC.
Development Programs
FCX-007 for Recessive Dystrophic Epidermolysis Bullosa
RDEB is the most severe form of dystrophic epidermolysis bullosa, or DEB, a congenital, progressive, devastatingly painful and debilitating
genetic disorder that often leads to death. RDEB is caused by a mutation of the
COL7A1
gene, the gene which encodes for type VII collagen, or
COL7, a protein that forms anchoring fibrils. Anchoring fibrils hold together the layers of skin, and without them, skin layers separate causing severe blistering, open wounds and scarring in response
to friction, including normal daily activities like rubbing or scratching. Children who inherit this condition are often called "butterfly children" because their skin can be as fragile as a
butterfly's wings. We estimate that there are approximately 1,100 - 2,500 RDEB patients in the U.S. Currently, treatments for RDEB address only the sequelae, including daily bandaging
(which can cost a patient in excess of $10,000 per month), hydrogel dressings, antibiotics, feeding tubes and surgeries.
Our
lead product candidate, FCX-007, is in clinical development for the treatment of RDEB. FCX-007 is a genetically-modified autologous fibroblast that encodes the gene for COL7 for
localized treatment of RDEB and is being developed in collaboration with Intrexon. By genetically modifying autologous fibroblasts
ex vivo
to produce
COL7, culturing them and then treating blisters and wounds locally via injection, FCX-007 offers the potential to address the underlying cause of the disease by providing high levels of COL7 directly
to the affected areas, thereby avoiding systemic treatment. In addition, we believe the autologous nature of the cells, localized delivery, use of an integrative vector and the low turnover rate of
the protein will contribute to long-term persistence of the COL7 produced by FCX-007.
FCX-007
has received Orphan Drug Designation for the treatment of DEB, including RDEB, Rare Pediatric Disease Designation for the treatment of RDEB and Fast Track Designation for the
treatment of RDEB from the United States Food and Drug Administration, or FDA.
The primary objective of this open-label trial is to evaluate the safety of FCX-007 in RDEB patients. Additionally, the trial will assess
(i) the mechanism of action of FCX-007 through the evaluation of type VII collagen expression and the presence of anchoring fibrils and (ii) the efficacy of FCX-007 through
intra-subject paired analysis of target wound area by comparing FCX-007 treated wounds to untreated wounds in Phase 1 and to wounds administered with sterile saline in Phase 2 through
the evaluation of digital imaging of wounds. Twelve patients are targeted to be treated with FCX-007 consisting of six adults in the Phase 1 portion of the trial and six patients in the
Phase 2
2
Table of Contents
portion
of the trial. Prior to conducting clinical trials on pediatric patients, we are required to obtain allowance from the FDA by submitting evidence of FCX-007 safety and benefit in adult patients
and data from its completed pre-clinical toxicology study.
We
are actively recruiting adult patients to complete enrollment in the Phase 1 portion of the trial and currently have four of the six adult patients enrolled. The patients in
the Phase 1 portion of the trial are divided into two equal cohorts in order to evaluate the safety of FCX-007 in each population type. One cohort is comprised of patients who have positive
expression of the non-collagenous portion of the COL7 protein (NC1+) and the other cohort is comprised of patients who do not express the non-collagenous portion of the protein
(NC1). Patients enrolled to date fulfilled the NC1+ cohort and also provided the first patient for the NC1 cohort. Two more patients are required for the
NC1 cohort to complete enrollment in the Phase 1 portion of the trial. The clinical trial protocol is designed to allow a cohort to move into the Phase 2 portion of the
trial even if the other cohort is still enrolling or in the follow-up evaluation period.
The
first adult patient in the NC1+ cohort in the Phase 1 portion of the Phase 1/2 clinical trial was dosed in the first quarter of 2017. In May 2017, the Data Safety Monitoring
Board, or DSMB,
recommended continuation of the Phase 1/2 clinical trial of FCX-007 for the treatment of RDEB, following a planned review of safety data from the first patient treated in the Phase 1 portion of
the trial. No product-related adverse events were reported. Based on the DSMB's recommendation, the remaining two patients in the NC1+ cohort in the Phase 1 portion of the trial were dosed in
June 2017.
In
September 2017, we reported interim results of the Phase 1/2 clinical trial of FCX-007. Three adult NC1+ patients were dosed with a single intradermal injection session of FCX-007 in
the margins of and across targeted wounds, as well as in separate intact skin sites. Five wounds were treated on the three subjects, ranging in size from 4.4cm
2
to 13.1cm
2
.
Data from these patients show FCX-007 was well-tolerated through 12 weeks post-administration. There were no serious adverse events and no product related adverse events reported.
The
targeted wounds were evaluated during a monitoring period prior to dosing and were observed to be open for up to eight months. Compared to the baseline measurement collected at Day 0
before the single intradermal injection session of FCX-007, at four weeks post-administration 100% (5/5) of wounds were > 75% healed. At 12 weeks post-administration, 80% (4/5) of wounds were >
70% healed. Various pharmacology signals for vector DNA, COL7 mRNA, or COL7 protein expression were detected throughout the data set in each patient for one or more assays up to 12 weeks
post-administration (qPCR, electron microscopy or immunofluorescence). Anchoring fibrils have not been detected to date, whereas expressed COL7 mRNA and COL7 protein have been confirmed in multiple
patient samples including one that detected linear expression of COL7 at the basement membrane zone. The Data Safety Monitoring Board for the trial reviewed the interim data and concluded that safety
and potential benefit were established, and allowed continuation of enrollment and dosing.
With
data from the first three patients meeting the primary trial objective of safety, we plan to increase expression and dosing of FCX-007. We expect to initiate the Phase 2
portion of the Phase 1/2 clinical trial of FCX-007, through the additional dosing of adult patients, in the fourth quarter of 2017. Furthermore, subject to FDA allowance, we expect to initiate
enrollment of pediatric patients in the Phase 2 portion of trial in the first quarter of 2018.
FCX-013 for Moderate to Severe Localized Scleroderma
Localized scleroderma is a chronic autoimmune skin disorder that manifests as excess production of extracellular matrix, specifically collagen,
resulting in thickening of the skin and connective tissue. Localized scleroderma encompasses several subtypes which are classified based on the depth and
3
Table of Contents
pattern
of the lesion(s). The moderate to severe forms of the disorder include linear, generalized, deep, pansclerotic and mixed morphea subtypes. Linear scleroderma is the most common subtype in
juvenile localized scleroderma and is associated with high morbidity and lifelong disability. Linear lesions of the limbs may cause limb length discrepancy due to impaired growth, muscle atrophy and
joint contracturesorthopedic complications are reported in 30-50% of patients. Current treatments for localized scleroderma, which include systemic or topical corticosteroids, UVA light
therapy and physical therapy, only address the symptoms of the disorder. We estimate that there are approximately 90,000 patients in the U.S. considered to have moderate to severe localized
scleroderma.
Our
second gene-therapy product candidate, FCX-013, is in pre-clinical development for the treatment of moderate to severe localized scleroderma. FCX-013 is an autologous fibroblast
genetically-modified using lentivirus and encoded for matrix metalloproteinase 1 (MMP-1), the protein responsible for breaking down collagen. FCX-013 incorporates Intrexon's proprietary RheoSwitch
Therapeutic System®, or RTS®, a biologic switch activated by an orally administered compound to control protein expression at the site of localized scleroderma lesions. FCX-013
is designed to be injected under the skin at the location of the fibrotic lesions where the genetically-modified fibroblast cells will produce MMP-1 to break down excess collagen accumulation. With
the FCX-013 therapy, the patient will take an oral compound to facilitate protein expression. Once the fibrosis is resolved, the patient will stop taking the oral compound which will halt further
MMP-1 production.
We
have successfully completed a proof-of-concept study for FCX-013 in which the primary objective was to determine whether FCX-013 had the potential to reduce dermal thickness in
fibrotic tissue. In this study, FCX-013 was evaluated in a bleomycin-induced scleroderma model utilizing severe combined immunodeficiency, or SCID, mice. Data from the study demonstrated that FCX-013
reduced dermal thickness of fibrotic tissue to levels similar to that of the non-treated control and further reduced the thickness of the sub-dermal muscle layer. Based upon these data and the FDA's
feedback to our pre-Investigational New Drug application, or IND, briefing package, we advanced FCX-013 into a pre-clinical dose-ranging study which has been completed. We expect to complete a
toxicology/biodistribution study and submit an IND application for FCX-013 to the FDA in the fourth quarter of 2017.
FCX-013
has received Orphan Drug Designation from the FDA for the treatment of localized scleroderma and Rare Pediatric Disease Designation for moderate to severe localized scleroderma.
New Gene Therapy Program for Arthritis and Related Conditions
Arthritis is a broad term that covers a group of more than 100 different types of diseases that affect the joints, as well as connective tissues
and organs, including the skin. According to the Centers for Disease Control and Prevention, arthritischaracterized by joint inflammation, pain and decreased range of
motionis the United States' most common cause of disability affecting more than 52 million adults as well as 300,000 children at a cost exceeding $120 billion.
Our
third gene-therapy program is in the research phase and is focused on the treatment of arthritis and related conditions. Our goal is to deliver a protein therapy locally to the joint
to provide sustained efficacy while avoiding key side effects typically associated with systemic therapy.
Risks Associated with Our Business
Our business is subject to a number of risks of which you should be aware before making an investment decision. These risks are discussed more
fully in the "Risk Factors" section of this prospectus immediately following this prospectus summary and in Part I, Item 1A "Risk Factors" of our Annual Report on Form 10-K filed
with the Securities and Exchange Commission, or SEC, on March 9, 2017 and in Part II, Item 1A. "Risk Factors" of our Quarterly Report on Form 10-Q for the
4
Table of Contents
quarterly
period ended June 30, 2017, filed with the SEC on August 9, 2017, which are incorporated by reference in this prospectus. These risks include the
following:
-
-
We have incurred significant losses since our inception, which we anticipate will continue for the foreseeable future. As of June 30,
2017, we had an accumulated deficit of $181.6 million.
-
-
We have never generated significant revenue from product sales and may never be profitable.
-
-
Our business is highly dependent on the success of FCX-007, our lead product candidate.
-
-
We may encounter difficulties enrolling or retaining subjects in our clinical trials.
-
-
Clinical product development is costly and time consuming and involves uncertain outcomes, and results of earlier studies and trials may not be
predictive of future trial results.
-
-
We may not be able to submit INDs, commence clinical trials or report data on the timelines we expect, and even if we are able to, the FDA may
not permit us to proceed.
-
-
If our product candidates fail to demonstrate quality, safety and efficacy to the satisfaction of regulatory authorities, we may incur
additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.
-
-
The net proceeds from this offering will not be sufficient to commercialize any of our product candidates and we will need to obtain additional
funding for commercialization. Failure to obtain additional funding when needed may force us to delay, limit or terminate our product development efforts or other operations.
-
-
There is substantial doubt relating to our ability to continue as a going concern as determined by management and as reflected in the report of
our independent public accounting firm. We will need to raise substantial additional capital to fund our operations.
-
-
We have relied and expect to rely on third parties to conduct aspects of our research and development and clinical trials. If they terminate
our arrangements, fail to meet deadlines or perform in an unsatisfactory manner, our business could be harmed.
-
-
The potential commercial success of any current or future product candidate will depend upon the degree of market acceptance by physicians,
patients, third-party payors and others in the medical community.
Corporate Information
Our corporate headquarters is located at 405 Eagleview Boulevard, Exton, Pennsylvania 19341. Our phone number is (484) 713-6000. Our
corporate website is www.fibrocell.com. We make available free of charge on our website our annual, quarterly and current reports, including amendments to such reports, as soon as reasonably
practicable after we electronically file such material
with, or furnish such material to, the SEC. Information contained on our website is not incorporated by reference into this prospectus, and you should not consider information contained on our website
as part of this prospectus.
5
Table of Contents
THE OFFERING
|
|
|
Common stock offered by us
|
|
shares ( shares if the underwriter's option to purchase additional shares is exercised
in full).
|
Common stock to be outstanding after this offering
|
|
shares
( shares if the underwriter's option to purchase additional shares is exercised in full).
|
Option to purchase additional shares
|
|
The underwriter has the option to purchase from us up to a maximum
of additional shares of common stock. The underwriter can exercise this option at any time within 30 days from the date of this prospectus.
|
Use of proceeds
|
|
We estimate that the net proceeds to us from this offering, after deducting underwriting discounts and commissions and
estimated offering expenses payable by us, will be approximately $ million ($ million if the underwriter's option to purchase
additional shares is exercised in full), assuming an offering price of $ per share, the last reported sale price of our common stock on the Nasdaq Capital Market
on , 2017. The actual offering price per share will be as determined between us and the underwriter at the time of pricing, and may be at a discount to the current market price. We currently
intend to use the net proceeds from this offering for the continued clinical and pre-clinical development of our product candidates, FCX-007 and FCX-013, and for the research of potential product candidates under the 2015 ECC, and for other general
corporate purposes, which may include working capital, research and development expenditures, the funding of in-licensing agreements for product candidates, additional technologies or other forms of intellectual property, expenditures relating to
manufacturing infrastructure and other capital expenditures and general and administrative expenses. See "Use of Proceeds" on page 15.
|
Risk Factors
|
|
An investment in our common stock involves a high degree of risk. See "Risk Factors" beginning on page 8 of this
prospectus and the similarly titled sections in the documents incorporated by reference into this prospectus.
|
Nasdaq Capital Market symbol
|
|
FCSC
|
Outstanding Shares
The number of shares of our common stock to be outstanding after this offering is based on 14,709,971 shares of our common stock outstanding as
of June 30, 2017, and excludes:
-
-
5,465,923 shares of our common stock issuable upon the conversion of our outstanding convertible promissory notes, including accrued interest
thereon, payable in shares of our common stock, outstanding as of June 30, 2017;
6
Table of Contents
-
-
3,480,000 shares of our common stock issuable upon the conversion of our Series A Convertible Preferred Stock, par value $0.001 per
share, or the Series A Preferred Stock, including accrued dividends thereon, payable in shares of our common stock, outstanding as of June 30, 2017;
-
-
1,123,826 shares of our common stock issuable upon the exercise of stock options outstanding as of June 30, 2017, at a weighted average
exercise price of $13.34 per share, of which stock options to purchase 650,479 shares of our common stock were then exercisable;
-
-
10,411,177 shares of our common stock issuable upon the exercise of warrants at a weighted average exercise price of $4.85 per share, all of
which warrants were then exercisable;
-
-
an aggregate of 1,396,423 shares of our common stock reserved for future grants of stock options (or other similar equity instruments) under
the Fibrocell Science, Inc. 2009 Equity Incentive Plan, as amended, or the Equity Incentive Plan; and
-
-
shares
(or shares if the underwriter's option to purchase additional shares is exercised in full) of our common
stock issuable upon exercise of the warrants being issued to the underwriter in connection with this offering.
Except
as otherwise indicated herein, all information in this prospectus, including the number of shares that will be outstanding after this offering, does not assume or give effect to
the exercise of options or warrants outstanding as of June 30, 2017.
Unless
otherwise indicated, all information contained in this prospectus assumes no exercise by the underwriter of its over-allotment option.
7
Table of Contents
RISK FACTORS
An investment in our common stock involves a high degree of risk. Before deciding whether to invest in our common stock,
you should carefully consider the risks described below and those discussed under the Section captioned "Risk Factors" contained in our Annual Report on Form 10-K for the fiscal year ended
December 31, 2016 and our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2017, which are incorporated by reference in this prospectus, together with the
information included in this prospectus and documents incorporated by reference herein, and in any free writing prospectus that we have authorized for use in connection with this offering. If any of
these risks actually occurs, our business, financial condition, results of operations or cash flow could be harmed. This could cause the trading price of our common stock to decline, resulting in a
loss of all or part of your investment.
Risks Related to this Offering
We have a significant number of outstanding convertible notes, convertible preferred stock, warrants and
stock options, and future sales of the underlying shares of common stock could adversely affect the market price of our common stock.
As of June 30, 2017, we had outstanding convertible notes convertible for 5,465,923 shares of our common stock (including accrued
interest thereon), outstanding convertible preferred stock convertible for 3,480,000 shares of our common stock (including accrued interest thereon), outstanding warrants exercisable for 10,411,177
shares of our common stock at a weighted average exercise price of $4.85 per share, all of which warrants were then exercisable, and outstanding stock options exercisable for 1,123,826 shares of our
common stock at a weighted average exercise price of $13.34 per share, of which stock options to purchase 650,479 shares of our common stock were then exercisable. Upon conversion of these notes or
preferred stock or exercise of these warrants or stock options, we would issue additional shares of our common stock. As a result, our current stockholders as a group would own a substantially smaller
interest in us and may have less influence on our management and policies than they now have. Furthermore, the holders may sell these shares in the public markets from time to time, without
limitations on the timing, amount or method of sale. As our stock price rises, the holders may convert more of their notes or preferred stock or exercise more of their warrants or stock options and
sell a large number of shares. This could cause the market price of our common stock to decline.
We may be required to raise additional financing by issuing new securities with terms or rights superior to
those of our existing securityholders, which could adversely affect the market price of shares of our common stock and our business.
We will require additional financing to fund future operations, including expansion in current and new markets, development and acquisition,
capital costs and the costs of any necessary implementation of technological innovations or alternative technologies. We may not be able to obtain financing on favorable terms, if at all. If we raise
additional funds by issuing equity securities, the percentage ownership of our current stockholders will be reduced, and the holders of the new equity securities may have rights superior to those of
our existing securityholders, which could adversely affect the market price of our common stock and the voting power of shares of our common stock. If we raise additional funds by issuing debt
securities, the holders of these debt securities would similarly have some rights senior to those of our existing securityholders, and the terms of these debt securities
could impose restrictions on operations and create a significant interest expense for us which could have a materially adverse effect on our business.
8
Table of Contents
Management will have broad discretion as to the use of the proceeds from this offering, and we may not use
the proceeds effectively.
Our management will have broad discretion with respect to the use of proceeds of this offering, including for any of the purposes described in
the section of this prospectus entitled "Use of Proceeds." You will be relying on the judgment of our management regarding the application of the proceeds of this offering. The results and
effectiveness of the use of proceeds are uncertain, and we could spend the proceeds in ways that you do not agree with or that do not improve our results of operations or enhance the value of our
common stock. Our failure to apply these funds effectively could harm our business, delay the development of our product candidates and cause the price of our common stock to decline.
You will experience immediate and substantial dilution in the net tangible book deficit per share of the
common stock you purchase.
Since the public offering price for our common stock in this offering is substantially higher than the net tangible book deficit per share of
our common stock outstanding prior to this offering, you will suffer immediate and substantial dilution in the net tangible book deficit of the common stock you purchase in this offering. See the
section titled "Dilution" below for a more detailed discussion of the dilution you will incur if you purchase shares in this offering.
Issuances of shares of our common stock or securities convertible into or exercisable for shares of our
common stock following this offering, as well as the exercise of options and warrants outstanding, will dilute your ownership interests and may adversely affect the future market price of our common
stock.
The issuance of additional shares of our common stock could be dilutive to stockholders if they do not invest in future offerings. We intend to
use the net proceeds from this offering for the continued clinical and pre-clinical development of our product candidates, FCX-007 and FCX-013, and for the research of potential product candidates
under the 2015 ECC, and for other general corporate purposes, which may include working capital, research and development expenditures, the funding of in-licensing agreements for product candidates,
additional technologies or other forms of intellectual property, expenditures relating to manufacturing infrastructure and other capital expenditures and general and administrative expenses. We may
seek additional capital through a combination of private and public equity offerings, debt financings, strategic partnerships and alliances and licensing arrangements, which may cause your ownership
interest to be diluted.
In
addition, we have a significant number of options and warrants to purchase shares of our common stock outstanding. If these securities are converted or exercised, you may incur
further dilution. Moreover, to the extent that we issue additional convertible notes, convertible preferred stock, options or warrants to purchase, or securities convertible into or exchangeable for,
shares of our common stock in the future and those options, warrants or other securities are exercised, converted or exchanged, stockholders may experience further dilution.
A significant portion of our total outstanding shares are eligible to be sold into the market, which could
cause the market price of our common stock to drop significantly, even if our business is doing well.
Sales of a substantial number of shares of our common stock in the public market, either by us or by our current stockholders, or the perception
that these sales could occur, could cause a decline in the market price of our securities. Such sales, along with any other market transactions, could adversely affect the market price of our common
stock.
Upon
completion of this offering, based on our shares outstanding as
of , 2017, we will
have shares of common stock outstanding based on the issuance and
sale of shares of our common stock in this offering. Of these shares,
only are
9
Table of Contents
subject
to a contractual lock-up with the underwriter for this offering for a period of days following this
offering. These shares can be sold, subject to any applicable volume
limitations under federal securities laws, after the earlier of the expiration of, or release from, the day
lock-up period. The balance of our outstanding shares of common stock,
including any shares purchased in this offering other than shares purchased by our current stockholders who are also subject to the contractual lock-up, may be resold into the public market
immediately without restriction, unless owned or purchased by our affiliates. Moreover, some of the holders of our common stock have the right, subject to specified conditions, to require us to file
registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders.
As
of June 30, 2017, there were approximately 2,511,915 shares subject to outstanding options or that are otherwise issuable under our Equity Incentive Plan, all of which shares
we have registered under the Securities Act of 1933, as amended, or the Securities Act, on a registration statement on Form S-8. These shares can be freely sold in the public market upon
issuance, subject to volume limitations applicable to affiliates and the lock-up agreements described above, to the extent applicable.
10
Table of Contents
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This prospectus contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of
historical facts, included in this prospectus or the documents incorporated herein by reference regarding our strategy, future operations, future product research or development, future financial
position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "goals," "estimate," "expect," "intend,"
"may," "might," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue" and similar expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these identifying words.
The
forward-looking statements in this prospectus include, among other things, statements about:
-
-
our expectations related to the use of the proceeds from this offering;
-
-
our expectation that our existing cash resources, plus the net proceeds of this offering, will be sufficient to enable us to fund our
operations into the second quarter of 2019;
-
-
future expenses and capital expenditures;
-
-
our estimates regarding expenses, future revenues, capital requirements and needs for, and ability to obtain, additional financing;
-
-
our plans to address our future capital requirements and the consequences of failing to do so;
-
-
our need to raise substantial additional capital to fund our operations;
-
-
our expectation to initiate the Phase 2 portion of the Phase 1/2 clinical trial of FCX-007 in the fourth quarter of 2017;
-
-
our expectation to initiate enrollment of pediatric patients in the Phase 2 portion of our Phase 1/2 clinical trial of
FCX-007 in the first quarter of 2018;
-
-
our expectation to complete a toxicology/biodistribution study and submit an IND for FCX-013 to the FDA in the fourth quarter of 2017;
-
-
our product development goals under our collaborations with Intrexon for all of our product candidates;
-
-
the potential benefits of Fast Track, Orphan Drug and Rare Pediatric Disease designations;
-
-
the potential advantages of our product candidates and technologies; and
-
-
the effect of legal and regulatory developments.
We
may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements.
Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary
statements included in this prospectus, particularly under "Risk Factors" on page 8 of this prospectus and the documents incorporated herein that we believe could cause actual results or events
to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint
ventures, collaborations or investments we may make.
You
should read this prospectus and the documents that we have filed as exhibits to this prospectus completely and with the understanding that our actual future results may be materially
different from what we expect.
11
Table of Contents
Except
as required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information or future events or developments. You should not
assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. Before deciding to purchase our securities, you should carefully
consider the risk factors discussed and incorporated by reference in this prospectus and the documents incorporated herein.
12
Table of Contents
SELECTED FINANCIAL DATA
You should read the following selected financial data together with our financial statements and the related notes contained in Item 8 of
Part II of our Annual Report on Form 10-K for the fiscal year ended December 31, 2016, which are incorporated by reference into this prospectus, except that share and per share
information for the periods ended December 31, 2016 and December 31, 2015 have been revised to reflect the 1-for-3 reverse stock split of our issued and outstanding shares of common
stock effective at the close of business on March 10, 2017.
We
have derived the statements of operations data for each of the two years ended December 31, 2016 and December 31, 2015 from the audited financial statements contained in
Item 8 of Part II of our Annual Report on Form 10-K for the year ended December 31, 2016.
The
historical financial information set forth below may not be indicative of our future performance and should be read together with "Management's Discussion and Analysis of Financial
Condition and
Results of Operations" and our historical financial statements and notes to those statements included in Item 7 of Part II and Item 8 of Part II, respectively, of our
Annual Report on Form 10-K for the year ended December 31, 2016, and any amendment or update thereto reflected in subsequent filings with the SEC, and all other annual, quarterly and
other reports that we file with the SEC after the date of the initial registration statement of which this prospectus forms a part and that also are incorporated herein by reference.
Fibrocell Science, Inc.
Statement of Operations Summary
($ in thousands except share and per share data)
|
|
|
|
|
|
|
|
|
|
(Adjusted for Stock Split)
Year Ended December 31,
|
|
|
|
2016
|
|
2015
|
|
Total revenue
|
|
$
|
355
|
|
$
|
492
|
|
Total cost of revenue
|
|
|
697
|
|
|
722
|
|
|
|
|
|
|
|
|
|
Gross loss
|
|
|
(342
|
)
|
|
(230
|
)
|
Operating Expenses
|
|
|
26,137
|
|
|
37,177
|
|
|
|
|
|
|
|
|
|
Operating loss
|
|
|
(26,479
|
)
|
|
(37,407
|
)
|
Other income (expense)
|
|
|
11,187
|
|
|
2,954
|
|
|
|
|
|
|
|
|
|
Loss before income taxes
|
|
|
(15,292
|
)
|
|
(34,453
|
)
|
Income taxes
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
$
|
(15,292
|
)
|
$
|
(34,453
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Per Share Information:
|
|
|
|
|
|
|
|
Net loss:
|
|
|
|
|
|
|
|
Basic
|
|
$
|
(1.04
|
)
|
$
|
(2.45
|
)
|
Diluted
|
|
$
|
(1.18
|
)
|
$
|
(2.55
|
)
|
Weighted average number of common shares outstanding:
|
|
|
|
|
|
|
|
Basic
|
|
|
14,641,528
|
|
|
14,059,360
|
|
|
|
|
|
|
|
|
|
Diluted
|
|
|
14,647,534
|
|
|
14,117,010
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
13
Table of Contents
Fibrocell Science, Inc.
Loss per Share Summary
($ in thousands except share and per share data)
|
|
|
|
|
|
|
|
|
|
(Adjusted for Stock Split)
Year Ended December 31,
|
|
|
|
2016
|
|
2015
|
|
Loss per shareBasic:
|
|
|
|
|
|
|
|
Numerator for basic loss per share
|
|
$
|
(15,292
|
)
|
$
|
(34,453
|
)
|
|
|
|
|
|
|
|
|
Denominator for basic loss per share
|
|
|
14,641,528
|
|
|
14,059,360
|
|
|
|
|
|
|
|
|
|
Basic loss per common share
|
|
$
|
(1.04
|
)
|
$
|
(2.45
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss per shareDiluted:
|
|
|
|
|
|
|
|
Numerator for basic loss per share
|
|
$
|
(15,292
|
)
|
$
|
(34,453
|
)
|
Adjust: Change in fair value of dilutive warrants outstanding
|
|
|
1,958
|
|
|
1,529
|
|
|
|
|
|
|
|
|
|
Numerator for diluted loss per share
|
|
$
|
(17,250
|
)
|
$
|
(35,982
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Denominator for basic loss per share
|
|
|
14,641,528
|
|
|
14,059,360
|
|
Plus: Incremental shares underlying "in the money" warrants outstanding
|
|
|
6,006
|
|
|
57,650
|
|
|
|
|
|
|
|
|
|
Denominator for diluted loss per share
|
|
|
14,647,534
|
|
|
14,117,010
|
|
|
|
|
|
|
|
|
|
Diluted loss per common share
|
|
$
|
(1.18
|
)
|
$
|
(2.55
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares underlying "in the money" options outstanding
|
|
|
150,120
|
|
|
629,449
|
|
Shares underlying "out of the money" options outstanding
|
|
|
1,218,563
|
|
|
391,197
|
|
Shares underlying "in the money" warrants outstanding
|
|
|
17,858
|
|
|
299,081
|
|
Shares underlying "out of the money" warrants outstanding
|
|
|
4,382,445
|
|
|
1,573,803
|
|
Shares underlying convertible notes
|
|
|
5,304,533
|
|
|
|
|
Shares underlying convertible accrued interest on convertible notes
|
|
|
40,137
|
|
|
|
|
14
Table of Contents
USE OF PROCEEDS
We estimate that the net proceeds from our issuance and sale of shares of our common stock in this offering will be
approximately $ million, or approximately $ million if the underwriter exercises its
over-allotment option in full, assuming a public offering price of
$ per share, the last reported sale price of our common stock on the Nasdaq Capital Market
on , 2017, after deducting the underwriting discounts and commissions and
estimated offering expenses payable by us.
A
$0.50 increase or decrease in the assumed public offering price of $ per share, the last reported sale price of our common stock on the Nasdaq Capital Market on
, 2017, would increase (decrease) the number of shares sold in this offering by
approximately million shares.
Similarly,
each increase (decrease) of 1,000,000 shares offered by us would increase (decrease) the net proceeds to us by approximately $ million, assuming the
assumed public offering price of $ per share remains the same, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us.
As
of June 30, 2017, we had cash and cash equivalents of $15.9 million. We intend to use the net proceeds from this offering to continue to fund the clinical and
pre-clinical development of FCX-007 and FCX-013, and for the research of potential product candidates under the 2015 ECC, and for other general corporate purposes, which may include, without
limitation:
-
-
working capital;
-
-
research and development expenditures;
-
-
the funding of in-licensing agreements for product candidates, additional technologies or other forms of intellectual property;
-
-
expenditures relating to manufacturing infrastructure and other capital expenditures; and
-
-
general administrative expenses.
This
expected use of net proceeds from this offering and our existing cash and cash equivalents represents our intentions based upon our current plans and business conditions, which
could change in the future as our plans and business conditions evolve. The amounts and timing of our use of the net proceeds from this offering will depend on a number of factors, such as the timing
and progress of our research and development efforts, the timing and progress of any partnering efforts, technological advances and the competitive environment for our product candidates. As of the
date of this prospectus, we cannot specify with certainty all of the particular uses for the net proceeds to us from
the sale of the securities offered by us hereunder. Accordingly, our management will have broad discretion in the timing and application of these proceeds. Pending application of the net proceeds as
described above, we intend to temporarily invest the proceeds in short-term, interest-bearing instruments.
Although
it is difficult to predict future liquidity requirements, we believe that the net proceeds from this offering, together with our existing cash resources, will be sufficient to
enable us to fund our operations into the second quarter of 2019. We have based this estimate on assumptions that may prove to be incorrect, and we could use our available capital resources sooner
than we currently expect.
15
Table of Contents
MARKET PRICE OF OUR COMMON STOCK
Our common stock trades on the Nasdaq Capital Market under the symbol "FCSC." The following table sets forth for the periods indicated the high
and low sale prices per share for our common stock, adjusted to reflect the effect of the reverse stock split of our common stock on March 10, 2017, as reported on the Nasdaq Capital Market for
the periods indicated:
|
|
|
|
|
|
|
|
|
|
Market Price
|
|
|
|
High
|
|
Low
|
|
First quarter 2015
|
|
$
|
5.99
|
|
$
|
2.38
|
|
Second quarter 2015
|
|
$
|
6.40
|
|
$
|
3.25
|
|
Third quarter 2015
|
|
$
|
7.60
|
|
$
|
3.68
|
|
Fourth quarter 2015
|
|
$
|
6.18
|
|
$
|
3.50
|
|
First quarter 2016
|
|
$
|
4.62
|
|
$
|
2.04
|
|
Second quarter 2016
|
|
$
|
3.78
|
|
$
|
0.91
|
|
Third quarter 2016
|
|
$
|
1.38
|
|
$
|
0.70
|
|
Fourth quarter 2016
|
|
$
|
1.05
|
|
$
|
0.52
|
|
First quarter 2017
|
|
$
|
2.64
|
|
$
|
0.62
|
|
Second quarter 2017
|
|
$
|
4.64
|
|
$
|
1.80
|
|
Third quarter 2017
|
|
$
|
4.17
|
|
$
|
2.41
|
|
Fourth quarter 2017 (through November 3, 2017)
|
|
$
|
3.29
|
|
$
|
1.90
|
|
As
of November 3, 2017, the closing price of our common stock as reported by the Nasdaq Capital Market was $2.05. As of October 31, 2017, we had approximately 31 holders of
record of our common stock. This number does not include beneficial owners whose shares were held in street name.
DIVIDEND POLICY
We have never declared or paid any cash dividends on our common stock. We currently intend to retain all of our future earnings, if any, to
finance the growth and development of our business. We do not intend to pay cash dividends in respect of our common stock in the foreseeable future.
16
Table of Contents
CAPITALIZATION
The following table sets forth our cash and cash equivalents and capitalization as of June 30,
2017:
-
-
on an actual basis;
-
-
on an as adjusted basis to give further effect to our issuance and sale of shares of our common stock in
this offering at an
assumed public offering price of $ per share, the last reported sale price for our common stock on the Nasdaq Capital Market
on , 2017, after deducting the underwriting
discounts and commissions and estimated offering expenses payable by us.
Our
capitalization following the closing of this offering will be adjusted based on the actual public offering price and other terms of this offering determined at pricing. You should
read this table together with our consolidated financial statements and the related notes and the "Management's Discussion and Analysis of Financial Condition and Results of Operations" section of our
Quarterly Report on Form 10-Q for the quarter ended June 30, 2017, filed with the SEC on August 9, 2017, which is incorporated by reference into this prospectus.
|
|
|
|
|
|
|
|
|
|
As of June 30, 2017
|
|
|
|
Actual
|
|
As Adjusted(1)
|
|
|
|
(in thousands)
|
|
Cash and cash equivalents
|
|
$
|
15,912
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrant liability
|
|
|
15,716
|
|
|
|
|
Derivative liability
|
|
|
1,194
|
|
|
|
|
Convertible promissory notes, net of debt discount $18,038*
|
|
|
|
|
|
|
|
Stockholders' equity (deficit)
|
|
|
|
|
|
|
|
Preferred stock, $0.001 par value per share; 5,000,000 shares authorized
|
|
|
|
|
|
|
|
Series A nonredeemable convertible preferred stock; 8,000 shares designated, 8,000 shares issued and outstanding as of June 30, 2017; aggregate
liquidation preference of $8,100 at June 30, 2017
|
|
|
|
|
|
|
|
Common stock, $0.001 par value per share; 150,000,000 shares authorized, 14,709,971 shares issued and outstanding, actual; 150,000,000 shares
authorized; shares issued and outstanding, as
adjusted
|
|
|
15
|
|
|
|
|
Additional paid-in capital
|
|
|
178,138
|
|
|
|
|
Accumulated deficit
|
|
|
(181,588
|
)
|
|
|
|
|
|
|
|
|
|
|
|
Total stockholders' equity (deficit)
|
|
|
(3,435
|
)
|
|
|
|
|
|
|
|
|
|
|
|
Total capitalization
|
|
$
|
13,475
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
-
*
-
The
principal value of the convertible promissory notes is $18,038 as of June 30, 2017.
-
(1)
-
Each
$0.50 increase (decrease) in the assumed public offering price per share would increase (decrease) the amount of cash and cash equivalents, working capital,
total assets, and total stockholders' equity by approximately $ million, assuming the number of shares offered by us, as set forth on the cover page of this prospectus,
remains
the same and after deducting underwriting discounts and commissions and estimated offering expenses payable by us. We may also increase or decrease the number of shares of common stock to be issued in
this offering. Each increase (decrease) of 1,000,000 shares offered by us would increase (decrease) the as adjusted amount of cash and cash
17
Table of Contents
equivalents,
working capital, total assets and total stockholders' equity by approximately $ million, assuming that the assumed public offering price remains the same, and after
deducting underwriting discounts and commissions and estimated offering expenses payable by us. The as adjusted information discussed above is illustrative only and will be adjusted based on the
actual public offering price and other terms of this offering as determined between us and the underwriter at pricing.
The
foregoing table and calculations are based on 14,709,971 shares of our common stock outstanding as of June 30, 2017, and excludes:
-
-
5,465,923 shares of our common stock issuable upon the conversion of our outstanding convertible promissory notes, including accrued interest
thereon, payable in shares of our common stock, outstanding as of June 30, 2017;
-
-
3,480,000 shares of our common stock issuable upon the conversion of our convertible preferred stock, including accrued dividends thereon,
payable in shares of our common stock, outstanding as of June 30, 2017;
-
-
1,123,826 shares of our common stock issuable upon the exercise of stock options outstanding as of June 30, 2017, at a weighted average
exercise price of $13.34 per share, of which stock options to purchase 650,479 shares of our common stock were then exercisable;
-
-
10,411,177 shares of our common stock issuable upon the exercise of warrants at a weighted average exercise price of $4.85 per share, all of
which warrants were then exercisable;
-
-
an aggregate of 1,396,423 shares of our common stock reserved for future grants of stock options (or other similar equity instruments) under
the Equity Incentive Plan; and
-
-
shares (or shares if the
underwriter's option to purchase additional shares is exercised in full) of our common
stock issuable upon exercise of the warrants being issued to the underwriter in connection with this offering.
18
Table of Contents
DILUTION
If you invest in our common stock in this offering, your ownership interest will be diluted immediately to the extent of the difference between
the public offering price per share of our common stock and the as adjusted net tangible book deficit per share of our common stock after this offering.
Our
historical net tangible book deficit as of June 30, 2017 was $(3.435) million, or $(0.23) per share of our common stock. Historical net tangible book deficit per share
represents the amount of our total tangible assets less total liabilities, divided by the number of shares of our common stock outstanding as of June 30, 2017.
After
giving effect to our issuance and sale of shares of our common stock in this offering at an assumed offering price of
$ per share, the last reported
sale price of our common stock on the Nasdaq Capital Market on , 2017, and after deducting the underwriting discounts and commissions and estimated
offering expenses payable by us, our
as adjusted net tangible book deficit as of June 30, 2017 would have been $ million, or $ per
share. This represents an immediate decrease in net tangible
book deficit per share of $ to existing stockholders and immediate dilution of $ per share to new investors
purchasing common stock in this offering. Dilution per share
to new investors is determined by subtracting as adjusted net tangible book deficit per share after this offering from the public offering price per share paid by new investors. The following table
illustrates this dilution on a per share basis:
|
|
|
|
|
|
|
|
Assumed public offering price per share
|
|
|
|
|
$
|
|
|
Historical net tangible book deficit per share as of June 30, 2017
|
|
$
|
(0.23
|
)
|
|
|
|
Increase in net tangible book deficit per share attributable to new investors
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As adjusted net tangible book deficit per share after this offering
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dilution per share to new investors
|
|
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Each
$0.50 increase (decrease) in the assumed public offering price of $ per share, the last reported sale price of our common stock on the Nasdaq Capital Market on
, 2017, would increase (decrease) our as adjusted net tangible book deficit per share after this offering by approximately
$ , and the dilution per share to new investors
purchasing shares in this offering by $ , assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting
underwriting discounts and commissions and estimated offering expenses payable by us. We may also increase or decrease the number of shares to be issued in this offering. Each increase (decrease) of
1,000,000 shares offered by us would increase (decrease) our as adjusted net tangible book deficit per share by $ and ($ ),
respectively, and the dilution per share to new
investors purchasing shares in this offering by $ and ($ ), respectively, assuming that the assumed public offering price remains
the same, and after deducting
underwriting discounts and commissions and estimated offering expenses payable by us. The information discussed above is illustrative only and will be adjusted based on the actual public offering
price and other terms of this offering as determined between us and the underwriter at pricing.
If
the underwriter exercises its over-allotment option in full, the as adjusted net tangible book deficit per share after this offering would be $ per share, the increase
in net tangible book deficit per share to existing stockholders would be $ per share and the dilution to new investors purchasing shares in this offering would be
$ per
share.
19
Table of Contents
The
foregoing table and calculations are based on 14,709,971 shares of our common stock outstanding as of June 30, 2017, and excludes:
-
-
5,465,923 shares of our common stock issuable upon the conversion of our outstanding convertible promissory notes, including accrued interest
thereon, payable in shares of our common stock, outstanding as of June 30, 2017;
-
-
3,480,000 shares of our common stock issuable upon the conversion of our convertible preferred stock, including accrued dividends thereon,
payable in shares of our common stock, outstanding as of June 30, 2017;
-
-
1,123,826 shares of our common stock issuable upon the exercise of stock options outstanding as of June 30, 2017, at a weighted average
exercise price of $13.34 per share, of which stock options to purchase 650,479 shares of our common stock were then exercisable;
-
-
10,411,177 shares of our common stock issuable upon the exercise of warrants at a weighted average exercise price of $4.85 per share, all of
which warrants were then exercisable;
-
-
an aggregate of 1,396,423 shares of our common stock reserved for future grants of stock options (or other similar equity instruments) under
the Equity Incentive Plan; and
-
-
shares (or shares if the
underwriter's option to purchase additional shares is exercised in full) of our common
stock issuable upon exercise of the warrants being issued to the underwriter in connection with this offering.
To
the extent that any convertible notes, convertible preferred stock, options or warrants are exercised or converted, new options are issued under our Equity Incentive Plan or we
otherwise issue additional shares of common stock in the future at a price less than the public offering price, there may be further dilution to new investors purchasing common stock in this offering.
20
Table of Contents
DESCRIPTION OF CAPITAL STOCK
The following description of our capital stock and provisions of our Restated Certificate of Incorporation, as amended, or the Certificate of
Incorporation, and our Fourth Amended and Restated Bylaws, as amended, or the Bylaws, are summaries and are qualified by reference to the Certificate of Incorporation and the Bylaws. We have filed
copies of these documents with the SEC as exhibits to our registration statement of which this prospectus forms a part.
Our
authorized capital stock consists of 150,000,000 shares of our common stock, par value $0.001 per share, and 5,000,000 shares of our preferred stock, par value $0.001 per share,
8,000 of which preferred stock is designated as Series A Convertible Preferred Stock, or the Series A Preferred Stock.
As
of June 30, 2017, we had 14,709,971 shares of our common stock and 8,000 shares of our Series A Preferred Stock issued and outstanding held by 25 and 5 stockholders of
record, respectively. This number does not include beneficial owners whose shares were held in street name.
Common Stock
Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and do not have
cumulative voting rights. Each election of directors by our stockholders will be determined by a plurality of the votes cast by the stockholders entitled to vote on the election. Holders of common
stock are entitled to receive proportionately any dividends as may be declared by our board of directors, subject to any preferential dividend rights of then outstanding preferred stock.
In
the event of our liquidation or dissolution, the holders of our common stock are entitled to receive proportionately all assets available for distribution to stockholders after the
payment of all debts and other liabilities and subject to the prior rights of any of our then outstanding preferred stock. Holders of our common stock have no preemptive, subscription, redemption or
conversion rights. The rights, preferences and privileges of holders of our common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of our
preferred stock that we may designate and issue in the future.
Preferred Stock
Under the terms of our Certificate of Incorporation, our board of directors is authorized to issue shares of preferred stock in one or more
series without stockholder approval. Our board of directors has the discretion to determine the rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion
rights, redemption privileges and liquidation preferences, of each series of preferred stock.
The
purpose of authorizing our board of directors to issue preferred stock and determine its rights and preferences is to eliminate delays associated with a stockholder vote on specific
issuances. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions, future financings and other corporate purposes, could have the effect of making it
more difficult for a third party to acquire, or could discourage a third party from seeking to acquire, a majority of our outstanding voting stock.
Series A Convertible Preferred Stock
On March 7, 2017, we entered into a Securities Purchase Agreement with certain of our existing investors pursuant to which we issued and
sold a total of 8,000 units, each a Unit and collectively the Units, for a purchase price of $1,000 per Unit, with each Unit consisting of (i) one share of our Series A Preferred Stock
convertible into 429 shares of our common stock and (ii) an accompanying warrant to purchase up to a number of shares of common stock equal to 100% of the conversion
21
Table of Contents
shares
issuable on March 7, 2017 pursuant to the shares of Series A Preferred Stock purchased by each investor. We refer to the foregoing transactions as the Series A Preferred
Stock Offering.
Each holder of Series A Preferred Stock may, at any time, elect to convert shares of Series A Preferred Stock into shares of our
common stock at the Conversion Price, subject to certain beneficial ownership limitations described below. The number of shares into which each share of Series A Preferred Stock is determined
by dividing the then stated value of the share of Series A Preferred Stock by the Conversion Price. The Conversion Price is defined as $2.32710 (subject to adjustment for stock splits, stock
dividends, stock combinations, recapitalizations or similar events).
In the event we effect certain mergers, consolidations, sales of substantially all of our assets, tender or exchange offers, reclassifications
or share exchanges in which our common stock is effectively converted into or exchanged for other securities, cash or property, we consummate a
business combination in which another person acquires 50% of the outstanding shares of our common stock, or any person or group becomes the beneficial owner of 50% of the aggregate ordinary voting
power represented by our issued and outstanding common stock, then, upon any subsequent conversion of the Series A Preferred Stock, the holders of such Series A Preferred Stock will have
the right to receive any shares of the successor or acquiring corporation and any additional consideration it would have been entitled to receive if it had been a holder of the number of shares of
common stock then issuable upon conversion in full (including accrued but unpaid dividends thereon) of the Series A Preferred Stock immediately prior to any of the foregoing transactions.
In
addition, we have agreed to have any successor entity in any of the foregoing transactions in which we are not the surviving entity assume in writing all of our obligations under the
Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock, or the Certificate of Designations.
The Series A Preferred Stock may not be converted and shares of our common stock may not be issued under the Certificate of Designation
with respect to such Series A Preferred Stock if, after giving effect to the conversion or issuance, a holder together with its affiliates would beneficially own in excess of 4.99% of the
outstanding shares of our common stock, or the Ownership Threshold; provided, however, that if a holder, together with its affiliates, otherwise comes to own a percentage of our common stock in excess
of the Ownership Threshold, the percentage limitation shall increase to 9.99%. Such increased percentage shall continue to apply until the holder is deemed to own an amount of shares less than or
equal to the Ownership Threshold of the outstanding shares of common stock, at which point the Ownership Threshold will apply again.
This
limitation on beneficial ownership may be increased, decreased or terminated, in the sole discretion of each holder of the Series A Preferred Stock, upon sixty-one
(61) days' written notice to us by such holder of Series A Preferred Stock.
Holders of the Series A Preferred Stock are entitled to receive, and we shall pay, cumulative dividends at a rate per share of 4% per
annum (calculated quarterly as a percentage of the applicable stated value per share for each quarterly period). After five years, holders of the Series A Preferred Stock are entitled to
receive cumulative dividends at a rate per share of 8% per annum
(calculated quarterly as a percentage of the applicable stated value per share for such quarterly period). Dividends
22
Table of Contents
on
a share of Series A Preferred Stock increase such share of Series A Preferred Stock's stated value and are payable by way of inclusion in the stated value (i) on the applicable
conversion date (but only with respect to the shares of Series A Preferred Stock being converted), (ii) upon our liquidation and (iii) upon the occurrence of a fundamental
transaction.
If
we, at any time while the Series A Preferred Stock is outstanding, pay a stock dividend or otherwise make a distribution or distributions payable in shares of our common stock
on shares of our common stock or any other common stock equivalents, each holder of Series A Preferred Stock shall be entitled to receive such dividend or distribution in such amounts as each
such holder of Series A Preferred Stock would have been entitled to receive, on a per share basis, if the shares of Series A Preferred Stock held by each such holder were converted into
shares of common stock at the time of payment of such stock dividend or distribution.
Upon our liquidation, dissolution or winding up, the holders of the Series A Preferred Stock shall be entitled to receive out of our
assets, whether capital or surplus, an amount equal to such holder's then stated value for each share of Series A Preferred Stock before any distribution to the holders of our common stock, any
class or series of preferred stock and all other common stock equivalents other than those securities which are explicitly senior or
pari passu
to the
Series A Preferred Stock in redemption, distribution of assets upon a liquidation or dividends. If there are insufficient assets to pay in full such amounts, then the available assets shall be
ratably distributed to the holders of the Series A Preferred Stock in accordance with the respective amounts that would be payable on such shares if all amounts payable thereon were paid in
full.
We are not obligated to redeem or repurchase any shares of Series A Preferred Stock. Shares of Series A Preferred Stock are not
otherwise entitled to any redemption rights, or mandatory sinking fund or analogous fund provisions.
Shares of Series A Preferred Stock will generally have no voting rights, except as required by law; provided, however, that without the
prior written consent of the holders of at least 70% of the then outstanding shares of Series A Preferred Stock, we may not: (i) alter or change adversely the powers, preferences or
rights given to the Series A Preferred Stock or alter or amend the Certificate of Designation; (ii) amend our Certificate of Incorporation or other charter documents in any manner that
adversely affects any rights of a holder of the Series A Preferred Stock; (iii) authorize or create any class of stock ranking as to redemption, distribution of assets upon liquidation
or dividends senior to, or otherwise
pari passu
with, the Series A Preferred Stock; (iv) declare or make any dividends other than dividend
payments or other distributions payable solely in the common stock; or (v) enter into any agreement with respect to any of the foregoing.
We will register the transfer of any shares of the Series A Preferred Stock in our preferred stock register, upon surrender of the
certificates evidencing such shares to be transferred, duly endorsed by a holder of shares of Series A Preferred Stock. Upon any such registration or transfer, a new certificate evidencing the
shares of Series A Preferred Stock so transferred will be issued to the transferee and a new certificate evidencing the remaining portion of the shares not so transferred, if any, will be
issued to the transferring holder, in each case, within three (3) business days.
23
Table of Contents
The Series A Preferred Stock is not currently listed on any national securities exchange or other nationally recognized trading system
and we do not plan on making an application to list the Series A Preferred Stock on any national securities exchange or other nationally recognized trading system. Our common stock issuable
upon conversion of shares of Series A Preferred Stock is listed on the Nasdaq Capital Market.
Warrants
As of June 30, 2017, we had outstanding:
-
-
warrants held by certain of our investors issued in connection with a preferred stock financing to purchase up to 46,430 shares of our common
stock at an exercise price of $2.10, which will remain exercisable until December 13, 2017;
-
-
warrants held by certain of our investors issued in connection with a 2012 convertibles notes financing to purchase up to 375,194 shares of our
common stock, at an exercise price of $7.50 per share, which will remain exercisable until June 1, 2018;
-
-
warrants held by certain of our investors to purchase up to an aggregate of 523,045 shares of our common stock, at an exercise price of $22.50
per share, which will remain exercisable until December 13, 2018;
-
-
warrants held by certain of our investors, or the 2016 Private Placement Warrants, to purchase up to an aggregate of 6,029,174 shares of our
common stock, at an exercise price of $4.50 per share, which will remain exercisable until September 7, 2021; and
-
-
warrants held by certain of our investors, and issued in connection with the Series A Convertible Preferred Offering to purchase up to
an aggregate of 3,437,334 shares of our common stock, at a weighted-average exercise price of $2.54 per share, which will remain exercisable until March 8, 2022.
These
warrants provide for adjustments in the event of specified mergers, reorganizations, reclassifications, stock dividends, stock splits or other changes in our corporate structure.
Options
As of June 30, 2017, options to purchase an aggregate of 1,123,826 shares of our common stock, at a weighted-average exercise price of
13.34 per share, were outstanding.
Delaware Anti-Takeover Law and Certain Charter and Bylaw provisions
Provisions of Delaware law and our Certificate of Incorporation and Bylaws could make the acquisition of our company through a tender offer, a
proxy contest or other means more difficult and could make the removal of incumbent officers and directors more difficult. We expect these provisions to discourage coercive takeover practices and
inadequate takeover bids and to encourage persons seeking to acquire control of our company to first negotiate with our board of directors. We believe that the benefits provided by our ability to
negotiate with the proponent of an unfriendly or unsolicited proposal outweigh the disadvantages of discouraging these proposals. We believe the negotiation of an unfriendly or unsolicited proposal
could result in an improvement of its terms.
Our
Certificate of Incorporation provides for our board of directors to be divided into three classes serving staggered terms. Approximately one-third of the board of directors will be
elected each year.
The provision for a classified board could prevent a party who acquires control of a majority of the outstanding voting stock from obtaining control of the board of directors until the second annual
24
Table of Contents
stockholders'
meeting following the date the acquirer obtains the controlling stock interest. The classified board provision could discourage a potential acquirer from making a tender offer or
otherwise attempting to obtain control of our company and could increase the likelihood that incumbent directors will retain their positions.
Our
Bylaws do not permit stockholders to call a special meeting of stockholders. Our Bylaws provide that special meetings of the stockholders may be called only by a majority of the
members of our board of directors, our Chairman of the board of directors, our Chief Executive Officer or our President. Our Bylaws require that all stockholder actions be taken by a vote of the
stockholders at an annual or special meeting, and do not permit our stockholders to act by written consent without a meeting. Our Bylaws provide for an advance notice procedure for stockholder
proposals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to the board of directors. At an annual meeting, stockholders may only
consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of the board of directors. Stockholders may also consider a proposal or
nomination by a person who was a stockholder of record on the record date for the meeting, who is entitled to vote at the meeting and who has given to our Secretary timely written notice, in proper
form, of his, her or its intention to bring that business before the meeting. The Bylaws do not give our board of directors the power to approve or disapprove stockholder nominations of candidates or
proposals regarding other business to be conducted at a special or annual meeting of the stockholders. However, our Bylaws may have the effect of precluding the conduct of business at a meeting if the
proper procedures are not followed. These provisions may also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer's own slate of directors or
otherwise attempting to obtain control of our company.
Our board of directors has the authority, without action by our stockholders, to designate and issue preferred stock in one or more series. Our
board of directors may also designate the rights, preferences and privileges of each series of preferred stock, any or all of which may be greater than the rights of the common stock. It is not
possible to state the actual effect of the issuance of any shares of preferred stock on the rights of holders of the common stock until our board of directors determines the specific rights of the
holders of the preferred stock. However, these effects might include: (a) restricting dividends on the common stock; (b) diluting the voting power of the
common stock; (c) impairing the liquidation rights of the common stock; and (d) delaying or preventing a change in control of our company without further action by our stockholders.
Registration Rights
On September 7, 2016, we entered into a registration rights agreement with certain holders of our convertible promissory notes, and
warrants in connection with a private placement transaction, pursuant to which we will register under the Securities Act for resale shares of our commons stock issuable upon the conversion of such
notes or the exercise of such warrants and any other shares held by the investors in the private placement. The registration rights agreement contains customary terms such as demand and piggyback
registration rights.
If
we fail, under certain circumstances to file and keep effective a registration statement with respect to the securities covered under the registration rights agreement, we have agreed
to pay liquidated damages to each investor in an amount equal to one percent (1.0%) of the aggregate amount invested by each such investor pursuant to the convertible promissory notes then owned by
each such investor for each 30-day period or pro rata for any portion thereof during which the failure to file or keep effective continues. The registration rights will terminate with respect to each
investor
25
Table of Contents
upon
the date each such investor ceases to hold registrable securities under the terms of the registration rights agreement.
Transfer Agent and Registrar
Our transfer agent and registrar for our common stock is Broadridge Corporate Issuer Solutions, Inc.
Nasdaq Capital Market
Our common stock is listed on the Nasdaq Capital Market under the symbol "FCSC."
26
Table of Contents
CERTAIN RELATIONSHIPS AND TRANSACTIONS WITH RELATED PERSONS
Since January 1, 2014, we have engaged in the following transactions with our directors, executive officers, holders of more than 5% of
our voting securities, and affiliates or immediate family members of our directors, executive officers, and holders of more than 5% of our voting securities. We believe that all of these transactions
were on terms as favorable as could have been obtained from unrelated third parties.
Intrexon Collaborations
We are a party to two separate exclusive channel collaboration agreements with Intrexon Corporation, or Intrexon, pursuant to which we are
Intrexon's exclusive channel collaborator in the development and commercialization of products within certain specified fields. We engage Intrexon for support services for the research and development
of product candidates covered under these agreements and reimburse Intrexon for its cost for time and materials for such work.
Our
first exclusive channel collaboration agreement with Intrexon was entered into in October 2012, and was subsequently amended in June 2013 and January 2014. We refer to this
collaboration as the 2012 ECC. FCX-007 and FCX-013, our gene-therapy product candidates for the treatment of recessive
dystrophic epidermolysis bullosa and linear scleroderma, respectively, are being developed under the 2012 ECC. During 2016, we incurred research and development expenses of $3.7 million under
the 2012 ECC. As of September 30, 2017, we have incurred research and development expenses of approximately $4.2 million in 2017 under the 2012 ECC.
In
December 2015, we entered into our second exclusive channel collaboration agreement with Intrexon, or the 2015 ECC. We are currently in the research phase for a gene-therapy product
for arthritis and related conditions under the 2015 ECC. During 2016, we did not incur any research and development expenses under the 2015 ECC, however, we paid Intrexon $10.0 million related
to an up-front technology access fee in January 2016. We have not incurred any research and development expenses under the 2015 ECC in 2017, as of September 30, 2017.
Randal
J. Kirk is the chairman of the board of directors and chief executive officer of Intrexon. Together with his affiliates, Mr. Kirk owns more than 50% of Intrexon's common
stock and approximately 38% of our common stock, as of October 31, 2017. Two of our directors, Julian Kirk (who is the son of Randal J. Kirk) and Marcus E. Smith, are officers of
Third Security, which is owned by Randal J. Kirk.
Participation in 2016 Private Placement
On September 7, 2016, we issued an aggregate of approximately $18.1 million in principal of convertible promissory notes, each a
Note and collectively, the Notes, and accompanying warrants to purchase an aggregate of 6,029,174 shares of our common stock in a private placement to institutional and accredited investors, or the
2016 Private Placement. The Notes bear interest at 4% per annum and have a stated maturity date of the earlier of (i) September 7, 2026 and (ii) one-hundred and eighty
(180) days after the date on which our product candidate, FCX-007, is approved by the FDA for the treatment of RDEB. Each individual Note holder has the right to require us to repay all or any
portion of the unpaid principal from time to time on or after September 7, 2021. With respect to accrued and unpaid interest on the Note, each Note holder may elect, at any time and from time
to time, to have any accrued and unpaid interest converted into shares of our common stock. In addition, each Note holder may elect to accelerate the repayment of all unpaid principal and accrued
interest under such holder's Note upon consummation of a specified change of control transaction or occurrence of certain events of default as specified in the Notes.
27
Table of Contents
In
addition, upon an event of default, the base interest rate (excluding any additional interest) for the Notes automatically increases to twelve percent (12%) per annum. Subject to any
applicable cure period set forth in the Notes, all amounts outstanding with respect to the Notes (principal and accrued interest) would become due and payable immediately upon an event of default. The
conversion price of the Notes, the exercise price of the accompanying warrants and the number of shares of our common stock issuable upon conversion of the Notes and exercise of the accompanying
warrants are each subject to adjustment upon certain corporate events, including stock dividends, stock splits and distributions of cash or other assets to our stockholders.
Certain
of our stockholders who held more than 5% of our voting securities at the time of the transaction and their affiliated entities purchased shares in our 2016 Private Placement.
Affiliates of Randal J. Kirk (including Intrexon) participated in the 2016 Private Placement, and were issued an aggregate of $6,762,500 in principal of Notes and 2016 Private Placement Warrants to
purchase an aggregate of 2,254,168 shares of common stock.
We
have elected to accrue all interest due on the Notes. In June 2017, we issued 14,895 shares of restricted common stock in connection with the conversion of an aggregate amount of
$51,609.79 of the Notes, with such amount representing $50,000.00 in unpaid principal under the Notes and $1,609.79 in accrued and unpaid interest under the Notes. In July 2017 we issued 7,195 shares
of restricted common stock in connection with the conversion of an aggregate amount of $25,876.87 of the Notes, with such amount representing $25,000 in unpaid principal under the Notes and $876.87 in
accrued and unpaid interest under the Notes. In August 2017 we issued 2,821 shares of restricted common stock in connection with the conversion of an aggregate amount of $10,379.04 of the Notes, with
such amount representing $10,000 in unpaid principal under the Notes and $379.04 in accrued and unpaid interest under the Notes.
Registration Rights Agreement
On September 7, 2016, we entered into a registration rights agreement with certain holders of the Notes and 2016 Private Placement
Warrants in connection with the 2016 Private Placement, pursuant to which we will register under the Securities Act for resale shares of our commons stock issuable upon the conversion of the Notes or
the exercise of the 2016 Private Placement Warrants and any other shares of our common stock held by the investors in the 2016 Private Placement. The registration rights agreement contains customary
terms such as demand and piggyback registration rights, which are described further in "Description of Capital StockRegistration Rights," above.
Participation in Series A Preferred Stock Offering
On March 7, 2017, we entered into a Securities Purchase Agreement with certain of our existing investors pursuant to which we issued and
sold a total of 8,000 Units for a purchase price of $1,000 per Unit, with each Unit consisting of (i) one share of our Series A Preferred Stock convertible into 429 shares of our common
stock and (ii) an accompanying warrant to purchase up to a number of shares of common stock equal to 100% of the conversion shares issuable on March 7, 2017 pursuant to the shares of
Series A Preferred Stock purchased by each investor, or the Series A Preferred Stock Offering. Certain of our stockholders who held more than 5% of our voting securities at the time of
the transaction and their affiliated entities purchased shares in our Series A Preferred Stock Offering Affiliates of Randal J. Kirk (including Intrexon) participated in the Series A
Preferred Stock Offering, and were issued an aggregate of 3,016 shares of Series A Preferred Stock and accompanying warrants to purchase 1,295,875 shares of common stock for aggregate gross
proceeds of $3,016,000. See "Description of Capital StockSeries A Convertible Preferred Stock" for more information about the Series A Preferred Stock.
28
Table of Contents
PRINCIPAL STOCKHOLDERS
The following table sets forth information with respect to the beneficial ownership of our common stock as of October 31, 2017
by:
-
-
each of our directors;
-
-
each of our named executive officers;
-
-
all of our current directors and executive officers as a group; and
-
-
each person, or group of affiliated persons, who is known by us to beneficially own more than 5% of our common stock based on currently
available Schedules 13D and 13G filed with the SEC.
The
column entitled "Percentage of Shares Beneficially Owned" is based on a total of 14,719,987 shares of our common stock outstanding as of October 31, 2017.
Beneficial
ownership is determined in accordance with the rules and regulations of the SEC and includes voting or investment power with respect to our common stock. Shares of our common
stock subject to options and warrants that are currently exercisable or exercisable within 60 days after October 31, 2017 are considered outstanding and beneficially owned by the person
holding the options or warrants for the purpose of calculating the percentage ownership of that person but not for the purpose of calculating the percentage ownership of any other person. Except as
otherwise noted, the persons and entities in this table have sole voting and investing power with respect to all of the shares of our common stock beneficially owned by them, subject to community
property laws, where applicable. Except as otherwise set forth below, the address of each beneficial owner is c/o Fibrocell Science, Inc., 405 Eagleview Blvd., Exton, Pennsylvania 19341.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Percentage of
shares beneficially
owned
|
|
|
|
Number of
shares
beneficially
owned
|
|
Name and Address of Beneficial Owner
|
|
Before
offering
|
|
After
offering
|
|
5% Stockholders:
|
|
|
|
|
|
|
|
|
|
|
Randal J. Kirk(1)
|
|
|
5,540,138
|
|
|
37.6
|
%
|
|
|
|
FMR LLC(2)
|
|
|
868,814
|
|
|
5.9
|
%
|
|
|
|
Directors and Named Executive Officers:
|
|
|
|
|
|
|
|
|
|
|
John Maslowski(3)
|
|
|
73,272
|
|
|
*
|
|
|
*
|
|
David Pernock(4)
|
|
|
248,000
|
|
|
1.7
|
%
|
|
|
|
Keith A. Goldan(5)
|
|
|
667
|
|
|
*
|
|
|
|
|
Michael F. Marino
|
|
|
|
|
|
*
|
|
|
|
|
Julian Kirk(6)
|
|
|
40,667
|
|
|
*
|
|
|
|
|
Marc Mazur(7)
|
|
|
50,335
|
|
|
*
|
|
|
|
|
Kelvin Moore(8)
|
|
|
47,520
|
|
|
*
|
|
|
|
|
Marcus E. Smith(6)
|
|
|
40,667
|
|
|
*
|
|
|
|
|
Christine St.Clare(9)
|
|
|
44,001
|
|
|
*
|
|
|
|
|
Douglas J. Swirsky(6)
|
|
|
40,667
|
|
|
*
|
|
|
|
|
All Current Executive Officers and Directors as a Group (7 persons)(10)
|
|
|
337,129
|
|
|
2.2
|
%
|
|
|
|
-
*
-
Less
than one percent.
-
(1)
-
Based
on the Schedule 13D/A filed by Randal J. Kirk on July 27, 2015, Third Security, LLC, or Third Security, has sole voting and investment
power with respect to 10,219,631 shares (3,406,544 on a post-split basis) of Fibrocell common stock held by
29
Table of Contents
NRM
VII Holdings I, LLC, or NRM VII Holdings, Kapital Joe, LLC, or Kapital Joe, and Mascara Kaboom, LLC, or Mascara Kaboom, and Intrexon has shared voting and investment power
with respect to 6,400,783 shares (2,133,594 on a post-split basis) of Fibrocell common stock held by Intrexon.
Based
on Schedule 13D/A filed by Third Security on September 9, 2016, or the 2016 13D/A, NRM VII Holdings, Intrexon, Kapital Joe, and Mascara Kaboom acquired an aggregate
of $6,762,500 principal amount of convertible promissory notes and accompanying warrants to purchase 6,762,500 shares (2,254,168 on a post-split basis) of our common stock in a private placement
transaction that closed on September 7, 2016. Unpaid principal and interest on the notes is convertible into shares of common stock at the option of the note holder at $1.13625 ($3.40875 on a
post-split basis), subject to adjustment.
Based
on Schedule 13D/A filed by Third Security on March 10, 2017, or the 2017 13D/A, NRM VII Holdings, Intrexon, Kapital Joe, and Mascara Kaboom acquired an aggregate of 3,016 units,
comprised of (i) 3,016 shares of Series A Preferred Stock convertible into 3,887,624 shares (1,293,864 on a post-split basis) of common stock and (ii) warrants to purchase
3,887,624 shares (1,295,875 on a post-split basis) of common stock.
According
to the 2016 13D/A and 2017 13D/A, the convertible promissory notes, the shares of Series A Preferred Stock and the warrants contain certain conversion and exercise restrictions. If
NRM VII Holdings, Intrexon, Kapital Joe and Mascara Kaboom exercised the warrants and converted the principal and accrued interest of the convertible promissory notes and the Series A Preferred
Stock, NRM VII Holdings, Intrexon, Kapital Joe and Mascara Kaboom would receive, in the aggregate,
(i) 3,550,043 shares (split-effected) of our common stock pursuant to exercise of the warrants, (ii) 1,983,863 (split-effected) of common stock underlying $6,762,500 outstanding
principal amount of convertible promissory notes, (iii) 87,999 shares (split-effected) of common stock underlying an estimated $299,969 of accrued interest on the convertible promissory notes
and (iv) 1,324,024 shares (split-effected) of common stock underlying the Series A Preferred Stock (inclusive of dividends through October 31, 2017 payable by way of inclusion in
the stated value of the Series A Preferred Stock, resulting in the beneficial ownership of approximately 57.6% of our common stock. NRM VII Holdings is managed by an affiliate that is managed
by Third Security which is owned by Mr. Kirk. Kapital Joe and Mascara Kaboom are managed by Third Security. Mr. Kirk could be deemed to have indirect beneficial ownership of the shares
of common stock directly beneficially owned by NRM VII Holdings, Intrexon, Kapital Joe and Mascara Kaboom. The address for Randal J. Kirk is c/o Third Security, 1881 Grove Avenue, Radford,
Virginia 24141.
-
(2)
-
Based
on the Schedule 13-G filed by FMR LLC on February 14, 2017, Fidelity SelectCo, LLC (SelectCo), 1225 17th Street, Suite,
1100, Denver, Colorado 80202, a wholly-owned subsidiary of FMR and an investment adviser registered under Section 203 of the Investment Advisers Act of 1940, is the beneficial owner of
2,606,440 shares (868,814 on a post-split basis) of Fibrocell common stock as a result of acting as investment adviser to various investment companies registered under Section 8 of the
Investment Company Act of 1940, or the SelectCo Funds. Abigail P. Johnson and FMR through its control of SelectCo, and the SelectCo Funds each has sole power to dispose of the 2,606,440 shares
(868,814 on a post-split basis) owned by the SelectCo Funds. The ownership of one investment company, Fidelity Select Biotechnology Portfolio, amounted to 2,432,240 shares (810,747 on a post-split
basis). Fidelity Select Biotechnology Portfolio has its principal business office at 245 Summer Street, Boston, Massachusetts 02210. Members of the family of Abigail P. Johnson, Chairman and Chief
Executive Officer of
30
Table of Contents
FMR,
are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR. The Johnson family group and all
other Series B stockholders have entered into a stockholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of
Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the stockholders' voting agreement, members of the Johnson family may be deemed,
under the Investment Company Act
of 1940, to form a controlling group with respect to FMR. The address for FMR is 245 Summer Street, Boston, Massachusetts 02210.
-
(3)
-
Consists
of (i) 819 shares of common stock and (ii) options to purchase an aggregate of 72,453 shares of our common stock exercisable within
60 days of October 31, 2017.
-
(4)
-
Mr. Pernock
resigned in December 2016. The share amounts set forth in the table consist of options to purchase 248,000 shares of common stock exercisable
within 60 days of October 31, 2017.
-
(5)
-
Mr. Goldan
resigned in January 2017. The share amounts set forth in the table consist of 667 shares of common stock held by Mr. Goldan as of
October 31, 2017.
-
(6)
-
The
share amounts set forth in the table consist solely of shares underlying one or more outstanding options to purchase our common stock exercisable within
60 days of October 31, 2017.
-
(7)
-
Consists
of (i) 3,000 shares of our common stock and (ii) options and warrants to purchase an aggregate of 47,335 shares of our common stock
exercisable within 60 days of October 31, 2017.
-
(8)
-
Consists
of (i) 1,519 shares of our common stock and (ii) options to purchase 46,001 shares of our common stock exercisable within 60 days of
October 31, 2017.
-
(9)
-
Consists
of (i) 3,334 shares of common stock and (ii) options to purchase 40,667 shares of our common stock exercisable within 60 days of
October 31, 2017.
-
(10)
-
Consists
of (i) 8,672 shares of common stock and (ii) options and warrants to purchase an aggregate of 328,457 shares of our common stock exercisable
within 60 days of October 31, 2017.
31
Table of Contents
UNDERWRITING
We have entered into an underwriting agreement dated , 2017, with
H.C. Wainwright & Co., LLC as the
sole book-running manager of this offering. Subject to the terms and conditions of the underwriting agreement, we have agreed to sell to the underwriter and the underwriter has agreed to purchase from
us, at the public offering price less the underwriting discounts and commissions set forth on the cover page of this prospectus, shares of our common
stock.
A
copy of the underwriting agreement has been filed as an exhibit to the registration statement of which this prospectus is a part. The shares of common stock we are offering are being
offered by the underwriter subject to certain conditions specified in the underwriting agreement.
We
have been advised by the underwriter that it proposes to offer the shares directly to the public at the public offering price set forth on the cover page of this prospectus. Any
shares sold by the underwriter to securities dealers will be sold at the public offering price less a selling concession not in excess of $ per share.
The
underwriting agreement provides that the underwriter's obligation to purchase the securities we are offering is subject to conditions contained in the underwriting agreement. The
underwriter is obligated to purchase and pay for all of the shares offered by this prospectus.
No
action has been taken by us or the underwriter that would permit a public offering of the common stock in any jurisdiction where action for that purpose is required. None of the
shares included in this offering may be offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with the offer and sales of any
of the shares be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons who
receive this prospectus are advised to inform themselves about and to observe any restrictions relating to this offering of the common stock and the distribution of this prospectus. This prospectus is
neither an offer to sell nor a solicitation of any offer to buy the common stock in any jurisdiction where that would not be permitted or legal.
The
underwriter has advised us that it does not intend to confirm sales to any accounts over which it exercises discretionary authority.
Underwriting Discounts, Commissions and Expenses
The following table shows the public offering price, underwriting discounts and commissions and proceeds, before expenses to us. These amounts
are shown assuming both no exercise and full exercise of the underwriter's option to purchase additional shares.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
|
Per Share
|
|
Without
Option
Exercise
|
|
With
Option
Exercise
|
|
Public offering price
|
|
|
|
|
|
|
|
|
|
|
Underwriting discounts and commissions
|
|
|
|
|
|
|
|
|
|
|
Proceeds, before expenses, to us
|
|
|
|
|
|
|
|
|
|
|
We
estimate the total expenses payable by us for this offering to be approximately $ million, which amount includes (i) an assumed underwriting discount of
$ ($ million if the underwriter's option to purchase additional shares is exercised in full) based
upon the assumed public offering price of $ per
share (the last reported sale price of our common stock on the Nasdaq Capital Market on ), (ii) $25,000 non-accountable expense allowance payable to
the underwriter,
(iii) reimbursement of the accountable expenses of the underwriter equal to $100,000
32
Table of Contents
(none
of which has been paid in advance), including the legal fees of the underwriter being paid by us, and (iv) other estimated expenses of approximately $ which include legal,
accounting, printing costs and various fees associated with the registration and listing of our shares.
Underwriter Warrants
We have agreed to issue to the underwriter warrants to purchase a number of shares of our common stock equal to 4% of the aggregate number of
shares of common stock sold in this offering. The underwriter warrants will have a term of five years from the effective date of this prospectus and an exercise price per share equal to 125% of the
public offering price for the shares sold in this offering. Pursuant to FINRA Rule 5110(g), the underwriter warrants and any shares issued upon exercise of the underwriter warrants shall not be
sold, transferred, assigned, pledged, or hypothecated, or be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of the
securities by any person for a period of 180 days immediately following the date of effectiveness or commencement of sales of this offering, except the transfer of any security: (i) by
operation of law or by reason of our reorganization; (ii) to any FINRA member firm participating in the offering and the officers or partners thereof, if all securities so transferred remain
subject to the lock-up restriction set forth above for the remainder of the time period; (iii) if the aggregate amount of our securities held by the underwriter or related persons do not exceed
1% of the securities being offered; (iv) that is beneficially owned on a pro rata basis by all equity owners of an investment fund, provided that no participating member manages or otherwise
directs investments by the fund and the participating members in the aggregate do not own more than 10% of the equity in the fund; or (v) the exercise or conversion of any security, if all
securities remain subject to the lock-up restriction set forth above for the remainder of the time period.
Right of First Refusal
We have also granted the underwriter, for a period of 10 months from the closing date of this offering, a right of first refusal to act
as sole book-running manager for each and every future public or private equity offering by us or any of our successors or subsidiaries. We have also agreed to a tail fee equal to the cash and warrant
compensation in this offering if any investor to which the underwriter introduced us with respect to this offering during the term of its engagement provides us with further capital in a public or
private offering or capital raising transaction, with certain exceptions, during the 12-month period following termination of our engagement of the underwriter.
Option to Purchase Additional Shares
We have granted to the underwriter an option, exercisable not later than 30 days after the date of this prospectus, to purchase up to an
additional shares of common stock at the public
offering price, less the underwriting discounts and commissions, set forth on the cover page of this prospectus, to cover over-allotments, if any. If any additional shares of common stock are
purchased pursuant to the option to purchase additional shares, the underwriter will offer these shares of common stock on the same terms as those on which the other shares of common stock are being
offered hereby.
Nasdaq Capital Market Listing
Our stock is currently traded on the Nasdaq Capital Market under the symbol "FCSC." On November 3, 2017, the last reported sale price of
our common stock was $2.05 per share.
Lock-up Agreements
Our officers and directors have agreed with the underwriter to be subject to a lock-up period of days following the
date of this
prospectus. This means that, during the applicable lock-up
33
Table of Contents
period,
such persons may not offer for sale, contract to sell, sell, distribute, grant any option, right or warrant to purchase, pledge, hypothecate or otherwise dispose of, directly or indirectly,
any shares of our common stock or any securities convertible into, or exercisable or exchangeable for, shares of our common stock. Certain limited transfers are permitted during the lock-up period if
the transferee agrees to these lock-up restrictions. We have also agreed in the underwriting agreement, subject to certain exceptions, to similar lock-up restrictions on the issuance and sale of our
securities for days following the closing of this offering. The underwriter may, in its sole discretion and without notice, waive the terms of any of these lock-up agreements.
Stabilization, Short Positions and Penalty Bids
The underwriter may engage in syndicate covering transactions, stabilizing transactions and penalty bids or purchases for the purpose of
pegging, fixing or maintaining the price of our common stock:
-
-
Syndicate covering transactions involve purchases of securities in the open market after the distribution has been completed in order to cover
syndicate short positions. Such a naked short position would be closed out by buying securities in the open market. A naked short position is more likely to be created if the underwriter is concerned
that there could be downward pressure on the price of the securities in the open market after pricing that could adversely affect investors who purchase in the offering.
-
-
Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specific maximum.
-
-
Penalty bids permit the underwriter to reclaim a selling concession from a syndicate member when the securities originally sold by the
syndicate member are purchased in a stabilizing or syndicate covering transaction to cover syndicate short positions.
These
syndicate covering transactions, stabilizing transactions and penalty bids may have the effect of raising or maintaining the market prices of our securities or preventing or
retarding a decline in the market prices of our securities. As a result, the price of our common stock may be higher than the price that might otherwise exist in the open market. Neither we nor the
underwriter make any representation or prediction as to the effect that the transactions described above may have on the price of our common stock. These transactions may be effected on the Nasdaq
Capital Market, in the over-the-counter market or on any other trading market and, if commenced, may be discontinued at any time.
In
connection with this offering, the underwriter also may engage in passive market making transactions in our common stock in accordance with Regulation M during a period before
the commencement of offers or sales of shares of our common stock in this offering and extending through the completion of
the distribution. In general, a passive market maker must display its bid at a price not in excess of the highest independent bid for that security. However, if all independent bids are lowered below
the passive market maker's bid that bid must then be lowered when specific purchase limits are exceeded. Passive market making may stabilize the market price of the securities at a level above that
which might otherwise prevail in the open market and, if commenced, may be discontinued at any time.
Neither
we nor the underwriter make any representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the prices of our
securities. In addition, neither we nor the underwriter make any representation that the underwriter will engage in these transactions or that any transactions, once commenced, will not be
discontinued without notice.
34
Table of Contents
Indemnification
We have agreed to indemnify the underwriter against certain liabilities, including certain liabilities arising under the Securities Act, or to
contribute to payments that the underwriter may be required to make for these liabilities.
Other Relationships
The underwriter and its respective affiliates have engaged in, and may in the future engage in, investment banking and other commercial dealings
in the ordinary course of business with us or our affiliates. The underwriter has received, or may in the future receive, customary fees and commissions for these transactions.
35
Table of Contents
LEGAL MATTERS
The validity of the shares of common stock offered hereby is being passed upon for us by Hogan Lovells US LLP, Philadelphia,
Pennsylvania. Lowenstein Sandler LLP, New York, New York is acting as counsel for the underwriter in connection with this offering.
EXPERTS
The financial statements incorporated in this Prospectus by reference to the Annual Report on Form 10-K for the year ended
December 31, 2016 have been so incorporated in reliance on the report (which contains an explanatory paragraph relating to the Company's ability to continue as a going concern as described in
Note 1 to the financial statements) of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and
accounting.
INCORPORATION BY REFERENCE
The SEC allows us to "incorporate by reference" information into this prospectus, which means that we can disclose important information to you
by referring you to another document filed separately with the SEC. The SEC file number for the documents incorporated by reference in this prospectus is 001-31564. The documents incorporated by
reference into this prospectus contain important information that you should read about us.
The
following documents are incorporated by reference into this document:
-
-
our Annual Report on Form 10-K for the year ended December 31, 2016, filed on March 9, 2017;
-
-
our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2017 and June 30, 2017, filed on May 10, 2017
and August 9, 2017, respectively;
-
-
those portions of our Definitive Proxy Statement on Schedule 14A filed on January 27, 2017 that are deemed "filed" with the SEC;
-
-
those portions of our Definitive Proxy Statement on Schedule 14A filed on April 27, 2017 that are deemed "filed" with the SEC;
and
-
-
our Current Reports on Form 8-K (other than portions thereof furnished under Item 2.02 or Item 7.01 of Form 8-K and
exhibits accompanying such reports that relate to such items) filed with the SEC on January 9, 2017, January 26, 2017, February 13, 2017, February 23, 2017, March 1,
2017, March 3, 2017, March 8, 2017, March 10, 2017, May 9, 2017, June 27, 2017, September 26, 2017 and October 4, 2017.
We
also incorporate by reference into this prospectus all documents (other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits filed
on such form that are related to such items) that are filed by us with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of the initial registration
statement of which this prospectus is a part and prior to the effectiveness of such registration statement and all documents that are filed by us with the SEC pursuant to Sections 13(a), 13(c),
14 or 15(d) of the Exchange Act after the date of this prospectus but prior to the termination of the offering. These documents include periodic reports, such as Annual Reports on Form 10-K,
Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, as well as proxy statements.
Any
statement contained herein or in a document incorporated or deemed to be incorporated by reference into this document will be deemed to be modified or superseded for purposes of the
document to the extent that a statement contained in this document or any other subsequently filed
36
Table of Contents
document
that is deemed to be incorporated by reference into this document modifies or supersedes the statement.
You
may request, orally or in writing, a copy of any or all of the documents incorporated herein by reference. These documents will be provided to you at no cost, by contacting:
Fibrocell Science, Inc., Attn: Office of the Corporate Secretary, 405 Eagleview Blvd., Exton, PA 19341. In addition, copies of any or all of the documents incorporated herein by reference may
be accessed at our website at http://www.fibrocell.com. The information on such website is not incorporated by reference and is not a part of this prospectus.
WHERE YOU CAN FIND MORE INFORMATION
We have filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to the shares of our common stock.
This prospectus, which constitutes part of the registration statement, does not include all of the information contained in the registration statement and the exhibits, schedules and amendments to the
registration statement. For further information with respect to us and our common stock, we refer you to the registration statement and to the exhibits and schedules to the registration statement.
Statements contained in this prospectus about the contents of any contract, agreement or other document are not necessarily complete, and, in each instance, we refer you to the copy of the contract,
agreement or other document filed as an exhibit to the registration statement. Each of these statements is qualified in all respects by this reference. You should rely only on information contained
in, or incorporated by reference into, this prospectus. We have not authorized anyone to provide you with information different from that contained in this prospectus or incorporated by reference in
this prospectus.
You
may read and copy the registration statement of which this prospectus is a part at the SEC's public reference room, which is located at 100 F Street, N.E., Room 1580,
Washington, DC 20549. You can request copies of the registration statement by writing to the SEC and paying a fee for the copying cost. Please call the SEC at 1-800-SEC-0330 for more information about
the operation of the SEC's public reference room. In addition, the SEC maintains an Internet website, which is located at
http://www.sec.gov,
that
contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC. You may access the registration statement of which this prospectus is
a part at the SEC's Internet website. Our reports on Forms 10-K, 10-Q and 8-K, and amendments to those reports, are also available for download, free of charge, as soon as reasonably
practicable after these reports are filed with the SEC, at our website at http://fibrocell.com. The content contained in, or that can be accessed through, our website is not a part of this prospectus.
37
Table of Contents
Shares
Common Stock
PRELIMINARY PROSPECTUS
Sole Book-Running Manager
H.C. Wainwright & Co.
, 2017
Table of Contents
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
Item 13. Other Expenses of Issuance and Distribution.
The following table sets forth the expenses to be incurred in connection with the offering described in this Registration Statement, other than
underwriting discounts and commissions, all of which will be paid by us. All amounts are estimates except the Securities and Exchange Commission, or SEC, registration fee and the Financial Industry
Regulatory Authority, Inc., filing fee.
|
|
|
|
|
|
|
Amount
|
|
SEC registration fee
|
|
$
|
3,006.68
|
|
Financial Industry Regulatory Authority, Inc. filing fee
|
|
|
4,122.50
|
|
Accountant's fees and expenses
|
|
|
|
*
|
Legal fees and expenses
|
|
|
|
*
|
Transfer agent's fees and expenses
|
|
|
|
*
|
Printing and engraving expenses
|
|
|
|
*
|
Miscellaneous
|
|
|
|
*
|
|
|
|
|
|
Total expenses
|
|
$
|
|
*
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
-
*
-
To
be filed by amendment.
Item 14. Indemnification of Directors and Officers.
Section 102 of the Delaware General Corporation Law, or the DGCL, permits a corporation to eliminate the personal liability of its
directors or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his or her duty of loyalty, failed to act in good faith, engaged in
intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit.
Our Certificate of Incorporation provides that no director shall be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duty as a director, notwithstanding any
provision of law imposing such liability, except to the extent that the DGCL prohibits the elimination or limitation of liability of directors for breaches of fiduciary duty.
Section 145
of the DGCL provides that a corporation has the power to indemnify a director, officer, employee or agent of the corporation and certain other persons serving at the
request of the corporation in related capacities against expenses (including attorneys' fees), judgments, fines and amounts paid in settlements actually and reasonably incurred by the person in
connection with an action, suit or proceeding to which he or she is or is threatened to be made a party by reason of such position, if such person acted in good faith and in a manner he or she
reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no
reasonable cause to believe his or her conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any
claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines
that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnification for such expenses which the Court of
Chancery or such other court shall deem proper.
Our
Certificate of Incorporation provides that we will indemnify each person who was or is a party or threatened to be made a party to any threatened, pending or completed action, suit
or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of us), by
II-1
Table of Contents
reason
of the fact that he or she is or was, or has agreed to become, our director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or
trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise (all such persons being referred to as an Indemnitee), or by reason of any action
alleged to have been taken or omitted in such capacity, against all expenses (including attorneys' fees), judgments, fines and amounts paid in settlement actually and reasonably incurred in connection
with such action, suit or proceeding and any appeal therefrom if such Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, and,
with respect to any criminal action or proceeding, he or she had no reasonable cause to believe his or her conduct was unlawful.
Our
Certificate of Incorporation also provides that we will indemnify any Indemnitee who was or is a party to an action or suit by or in the right of us to procure a judgment in our
favor by reason of the fact that the Indemnitee is or was, or has agreed to become, our director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer,
partner, employee or trustee or, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise, or by reason of any action alleged to have been taken or
omitted in such capacity, against all expenses (including attorneys' fees) and, to the extent permitted by law, amounts paid in settlement actually and reasonably incurred in connection with such
action, suit or proceeding, and any appeal therefrom, if the Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, except that
no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to us, unless a court determines that, despite such
adjudication but in view of all of the circumstances, he or she is entitled to indemnification of such expenses. Notwithstanding the foregoing, to the extent that any Indemnitee has been successful,
on the merits or otherwise, he or she will be indemnified by us against all expenses (including attorneys' fees) actually and reasonably incurred by him or her or on his or her behalf in connection
therewith. If we do not assume the defense, expenses must be advanced to an Indemnitee under certain circumstances.
We
have entered into indemnification agreements with our directors and executive officers. In general, these agreements provide that we will indemnify the director or executive officer
to the fullest extent permitted by law for claims arising in his or her capacity as a director or officer of our company or in connection with their service at our request for another corporation or
entity. The indemnification agreements also provide for procedures that will apply in the event that a director or executive officer makes a claim for indemnification and establish certain
presumptions that are favorable to the director or executive officer.
We
maintain a general liability insurance policy that covers certain liabilities of our directors and officers arising out of claims based on acts or omissions in their capacities as
directors or officers.
The
underwriting agreement we will enter into in connection with the offering of common stock being registered hereby provides that the underwriter will indemnify, under certain
conditions, our directors and officers (as well as certain other persons) against certain liabilities arising in connection with such offering.
Insofar
as the forgoing provisions permit indemnification of directors, executive officers, or persons controlling us for liability arising under the Securities Act of 1933, as amended,
or the Securities Act, we have been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.
II-2
Table of Contents
Item 15. Recent Sales of Unregistered Securities.
2016 Private Placement
On September 7, 2016, we issued an aggregate of approximately $18.1 million in principal of Notes and 2016 Private Placement
Warrants to purchase an aggregate of 6,029,174 shares of common stock in a private placement to institutional and accredited investors.
The
securities sold in this private placement were sold in reliance on the exemption from registration afforded by Section 4(a)(2) of the Securities Act and Rule 506(c) of
Regulation D promulgated under the Securities Act. Each of the investors represented that it was an accredited investor, as such term is defined in Rule 501(a) of Regulation D
under the Securities Act, and that it was acquiring the shares for investment only and not with a view towards, or for resale in connection with, the public sale or distribution thereof.
Conversion of 2016 Convertible Notes
In June 2017, we issued 14,895 shares of restricted common stock in connection with the conversion of an aggregate amount of $51,609.79 of the
Notes, with such amount representing $50,000.00 in unpaid principal under the Notes and $1,609.79 in accrued and unpaid interest under the Notes.
In
July 2017 we issued 7,195 shares of restricted common stock in connection with the conversion of an aggregate amount of $25,876.87 of the Notes, with such amount representing $25,000
in unpaid principal under the Notes and $876.87 in accrued and unpaid interest under the Notes.
In
August 2017 we issued 2,821 shares of restricted common stock in connection with the conversion of an aggregate amount of $10,379.04 of the Notes, with such amount representing
$10,000 in unpaid principal under the Notes and $379.04 in accrued and unpaid interest under the Notes.
These
shares of our common stock were issued in reliance on the exemption from registration provided by Section 3(a)(9) of the Securities Act, there was no additional
consideration paid upon the conversion of the promissory notes and we did not receive any additional proceeds in connection with the issuance of the unregistered shares of common stock.
Item 16. Exhibits and Financial Statement Schedules.
The exhibits to the registration statement are listed in the Exhibit Index attached hereto and incorporated by reference herein.
Item 17. Undertakings.
(b) The
undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant's annual
report pursuant to section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan's annual report pursuant to
section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the
securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(e) The
undersigned registrant hereby undertakes to deliver or cause to be delivered with the prospectus, to each person to whom the prospectus is sent or given, the latest
annual report to security holders that is incorporated by reference in the prospectus and furnished pursuant to and meeting the requirements of Rule 14a-3 or Rule 14c-3 under the
Securities Exchange Act of 1934; and, where interim financial information required to be presented by Article 3 of Regulation S-X are not set forth in the prospectus, to deliver, or
cause to be delivered to each person to whom the prospectus is sent or
II-3
Table of Contents
given,
the latest quarterly report that is specifically incorporated by reference in the prospectus to provide such interim financial information.
(h) Insofar
as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant
pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as
expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by
a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with
the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the
question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.
(i) The
undersigned registrant hereby undertakes that:
(1) For
purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration
statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b) (1) or (4) or 497(h) under the Securities Act
shall be deemed to be part of this registration statement as of the time it was declared effective.
(2) For
the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a
new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
II-4
Table of Contents
EXHIBIT INDEX
|
|
|
|
EXHIBIT
NO.
|
|
IDENTIFICATION OF EXHIBIT
|
|
1.1
|
#
|
Form of Underwriting Agreement
|
|
|
|
|
|
2.1
|
|
Debtors' First Amended Joint Plan of Reorganization dated July 30, 2009 and Disclosure Statement (incorporated by reference
to as Exhibit 10.2 to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2009, filed August 12, 2009 and as Exhibit 99.1 to our Form 8-K, filed September 2, 2009)
|
|
|
|
|
|
3.1
|
|
Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K,
filed December 13, 2012)
|
|
|
|
|
|
3.2
|
|
Certificate of Amendment of the Restated Certificate of Incorporation filed April 26, 2013 (incorporated by reference to
Exhibit 3.1 to our Current Report on Form 8-K, filed April 29, 2013)
|
|
|
|
|
|
3.3
|
|
Certificate of Amendment to the Company's Restated Certificate of Incorporation, as amended, filed July 19, 2013
(incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K filed July 22, 2013)
|
|
|
|
|
|
3.4
|
|
Certificate of Amendment of the Restated Certificate of Incorporation filed July 12, 2016 (incorporated by reference to
Exhibit 3.1 to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2016, filed August 4, 2016)
|
|
|
|
|
|
3.5
|
|
Fourth Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to our Quarterly Report on
Form 10-Q for the quarter ended March 31, 2015, filed May 8, 2015)
|
|
|
|
|
|
3.6
|
|
Amendment to Fourth Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to our Quarterly
Report on Form 10-Q for the quarter ended March 31, 2015, filed May 8, 2015)
|
|
|
|
|
|
3.7
|
|
Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock
(incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K, filed March 8, 2017)
|
|
|
|
|
|
3.8
|
|
Certificate of Amendment of the Restated Certificate of Incorporation of the Company (incorporated by reference to
Exhibit 3.1 to our Current Report on Form 8-K, filed March 10, 2017)
|
|
|
|
|
|
4.1
|
|
Form of Common Stock Certificate (incorporated by reference to Exhibit 4.1 to our Quarterly Report on Form 10-Q for the
quarter ended September 30, 2009, filed November 23, 2009)
|
|
|
|
|
|
4.2
|
|
Form of Common Stock Purchase Warrant used for the Series E Preferred Stock offering (incorporated by reference to
Exhibit 4.1 to our Current Report on Form 8-K, filed May 14, 2012)
|
|
|
|
|
|
4.3
|
|
Form of Amended and Restated Common Stock Purchase Warrant issued to our prior 12.5% Note holders (incorporated by reference to
Exhibit 10.5 to our Current Report on Form 8-K, filed October 9, 2012)
|
|
|
|
|
|
4.4
|
|
Form of Convertible Promissory Note (incorporated by reference to Exhibit 4.1 to our Current Report on
Form 8-K, filed September 8, 2016)
|
|
|
|
|
|
4.5
|
|
Form of Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.2 to our Current Report on
Form 8-K, filed September 8, 2016)
|
|
|
|
|
II-5
Table of Contents
|
|
|
|
EXHIBIT
NO.
|
|
IDENTIFICATION OF EXHIBIT
|
|
4.6
|
|
Form of Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.1 to our Current Report on
Form 8-K, filed March 8, 2017)
|
|
|
|
|
|
4.7
|
#
|
Form of Underwriter's Common Stock Purchase Warrant
|
|
|
|
|
|
5.1
|
#
|
Form of Opinion of Hogan Lovells US LLP
|
|
|
|
|
|
10.1
|
|
Lease Agreement between Isolagen, Inc. and The Hankin Group dated April 7, 2005 (incorporated by reference to
Exhibit 10.1 to our Current Report on Form 8-K, filed April 12, 2005)
|
|
|
|
|
|
10.2
|
|
Amendment to Lease Agreement between Fibrocell Science, Inc. and The Hankin Group dated February 17, 2012
(incorporated by reference to Exhibit 10.17 to our Annual Report on Form 10-K for the fiscal year ended December 31, 2011, filed March 30, 2012)
|
|
|
|
|
|
10.3
|
|
Securities Purchase Agreement dated October 5, 2012 (incorporated by reference to Exhibit 10.1 to our Current Report
on Form 8-K, filed October 9, 2012)
|
|
|
|
|
|
10.4
|
|
Registration Rights Agreement dated October 5, 2012 (incorporated by reference to Exhibit 10.2 to our Current Report
on Form 8-K, filed October 9, 2012)
|
|
|
|
|
|
10.5
|
|
Stock Issuance Agreement dated October 5, 2012 between the Company and Intrexon Corporation (incorporated by reference to
Exhibit 10.3 to our Current Report on Form 8-K, filed October 9, 2012)
|
|
|
|
|
|
10.6
|
|
Amendment and Conversion Agreement dated October 5, 2012 between the Company and the Holders of the Company's Notes
(incorporated by reference to Exhibit 10.4 to our Current Report on Form 8-K, filed October 9, 2012)
|
|
|
|
|
|
10.7
|
|
Exclusive Channel Collaboration Agreement between Intrexon Corporation and Fibrocell Science, Inc. (incorporated by
reference to Exhibit 10.21 to our Annual Report on Form 10-K for the fiscal year ended December 31, 2012, filed April 1, 2013)
|
|
|
|
|
|
10.8
|
|
First Amendment to Exclusive Channel Collaboration Agreement between the Company and Intrexon Corporation dated June 28,
2013 (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K, filed July 1, 2013)
|
|
|
|
|
|
10.9
|
|
Supplemental Stock Issuance Agreement between the Company and Intrexon Corporation dated June 28, 2013 (incorporated by
reference to Exhibit 10.2 to our Current Report on Form 8-K, filed July 1, 2013)
|
|
|
|
|
|
10.10
|
|
Second Amendment to Exclusive Channel Collaboration Agreement between the Company and Intrexon Corporation dated January 10,
2014 (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K, filed January 13, 2014)
|
|
|
|
|
|
10.11
|
|
Supplemental Stock Issuance Agreement between the Company and Intrexon Corporation dated January 10, 2014 (incorporated by
reference to Exhibit 10.2 to our Current Report on Form 8-K, filed January 13, 2014)
|
|
|
|
|
|
10.12
|
|
Letter Agreement to Exclusive Channel Collaboration Agreement, as amended, between Fibrocell Science, Inc. and Intrexon
Corporation dated September 29, 2015 (incorporated by reference to Exhibit 10.2 to our Quarterly Report on Form 10-Q for the quarter ended September 30, 2015, filed November 5, 2015)
|
|
|
|
|
|
10.13
|
¨
|
Exclusive Channel Collaboration Agreement, dated December 31, 2015, between Fibrocell Science, Inc. and
Intrexon Corporation (incorporated by reference to Exhibit 99.1 to our Current Report on Form 8-K, filed January 4, 2016)
|
II-6
Table of Contents
|
|
|
|
EXHIBIT
NO.
|
|
IDENTIFICATION OF EXHIBIT
|
|
10.14
|
|
Fibrocell Science, Inc. 2009 Equity Incentive Plan, as amended and restated as of March 11, 2017 (incorporated by
reference to Exhibit 10.2 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2017, filed May 10, 2017)
|
|
|
|
|
|
10.15
|
|
Amendment to the Fibrocell Science, Inc. 2009 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to our
Quarterly Report on Form 10-Q for the quarter ended June 30, 2016, filed August 4, 2016)
|
|
|
|
|
|
10.16
|
|
Form of Nonqualified Stock Option Agreement for Employee Grants under Fibrocell Science, Inc. 2009 Equity
Incentive Plan (incorporated by reference to Exhibit 10.2 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2015, filed May 8, 2015)
|
|
|
|
|
|
10.17
|
|
Form of Nonqualified Stock Option Agreement for Director Grants under Fibrocell Science, Inc. 2009 Equity
Incentive Plan (incorporated by reference to Exhibit 10.3 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2015, filed May 8, 2015)
|
|
|
|
|
|
10.18
|
|
Form of Incentive Stock Option Agreement for Employee Grants under Fibrocell Science, Inc. 2009 Equity
Incentive Plan (incorporated by reference to Exhibit 10.4 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2015, filed May 8, 2015)
|
|
|
|
|
|
10.19
|
|
Amendment to Stock Option Agreement by and between the Company and David Pernock dated March 11, 2015 (incorporated
by reference to Exhibit 10.22 to our Annual Report on Form 10-K for the fiscal year ended December 31, 2014, filed March 13, 2015)
|
|
|
|
|
|
10.20
|
|
Employment Agreement between the Company and David Pernock dated November 15, 2013 (incorporated by reference to
Exhibit 10.1 to our Current Report on Form 8-K, filed November 18, 2013)
|
|
|
|
|
|
10.21
|
|
Employment Agreement between the Company and Keith A. Goldan dated March 18, 2015 (incorporated by reference to
Exhibit 10.1 to our Current Report on Form 8-K, filed March 18, 2015)
|
|
|
|
|
|
10.22
|
|
Employment Agreement between the Company and Michael F. Marino dated June 1, 2015 (incorporated by reference
to Exhibit 10.1 to our Form 10-Q for the quarter ended June 30, 2015, filed August 7, 2015)
|
|
|
|
|
|
10.23
|
|
Employment Agreement between the Company and John Maslowski dated September 14, 2015 (incorporated by
reference to Exhibit 10.1 to our Current Report on Form 8-K, filed September 16, 2015)
|
|
|
|
|
|
10.24
|
|
Separation Agreement and Release, dated November 4, 2016, and Supplemental Release, dated January 4, 2017, by
and between the Company and Keith A. Goldan (incorporated by reference to Exhibit 10.24 to our Annual Report on Form 10-K, filed March 9, 2017)
|
|
|
|
|
|
10.25
|
|
Separation Agreement and General Release by and between the Company and David Pernock dated December 18, 2016
(incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K, filed December 19, 2016)
|
|
|
|
|
|
10.26
|
|
Offer Letter by and between the Company and John M. Maslowski dated December 18, 2016 (incorporated by reference to
Exhibit 10.2 to our Current Report on Form 8-K, filed December 19, 2016)
|
|
|
|
|
|
10.27
|
|
Separation Agreement and General Release by and between the Company and Michael F. Marino dated January 25,
2017 (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K, filed January 26, 2017)
|
|
|
|
|
II-7
Table of Contents
|
|
|
|
EXHIBIT
NO.
|
|
IDENTIFICATION OF EXHIBIT
|
|
10.28
|
|
Separation Agreement and General Release by and between the Company and Kimberly M. Smith dated March 3, 2017 (incorporated by
reference to Exhibit 10.1 to our Current Report on Form 8-K, filed March 3, 2017)
|
|
|
|
|
|
10.29
|
|
Agreement for the Purchase and Sale of Convertible Debt and Common Stock Warrants dated August 9, 2016 (incorporated by
reference to Exhibit 10.1 to our Quarterly Report on Form 10-Q for the quarter ended September 30, 2016, filed November 3, 2016)
|
|
|
|
|
|
10.30
|
|
Form of Registration Rights Agreement (incorporated by reference to Exhibit 10.1 to our Current Report on
Form 8-K, filed September 8, 2016)
|
|
|
|
|
|
10.31
|
|
Controlled Equity Offering Sales Agreement by and between the Company and Cantor Fitzgerald & Co.
dated January 21, 2016 (incorporated by reference to Exhibit 10.1 of our Current Report on Form 8-K, filed January 21, 2016)
|
|
|
|
|
|
10.32
|
|
Form of Securities Purchase Agreement by and between the Company and other signatories thereto dated March 7,
2017 (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K, filed March 8, 2017)
|
|
|
|
|
|
10.33
|
|
Engagement Letter, dated May 8, 2017, by and between the Company and AC Lordi (incorporated by reference to
Exhibit 10.1 to our Current Report on Form 8-K, filed May 9, 2017)
|
|
|
|
|
|
21
|
|
Subsidiaries of Fibrocell Science, Inc. (incorporated by reference to Exhibit 21.1 to our Annual Report on
Form 10-K for the fiscal year ended December 31, 2016, filed March 09, 2017 (File No. 001-31564)
|
|
|
|
|
|
*23.1
|
|
Consent of PricewaterhouseCoopers LLP
|
|
|
|
|
|
23.2
|
#
|
Consent of Hogan Lovells US LLP (included in Exhibit 5.1)
|
|
|
|
|
|
*24.1
|
|
Power of attorney (included on the signature page of this registration statement)
|
-
#
-
To
be filed by amendment.
-
*
-
Filed
herewith.
-
-
Indicates
management contract or compensatory plan or arrangement.
-
¨
-
Confidential
treatment has been granted as to certain portions of this exhibit pursuant to Rule 406 of the Securities
Act of 1933, as amended, or Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
II-8
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its
behalf by the undersigned, thereunto duly authorized in the city of Exton, Commonwealth of Pennsylvania, on this 6th day of November, 2017.
|
|
|
|
|
|
|
|
|
FIBROCELL SCIENCE, INC.
|
|
|
By:
|
|
/s/ JOHN M. MASLOWSKI
|
|
|
|
|
Name:
|
|
John M. Maslowski
|
|
|
|
|
Title:
|
|
President and Chief Executive Officer
|
POWER OF ATTORNEY
KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints John M. Maslowski and Sean D. Buckley as his
or her true and lawful attorney-in-fact and agent, with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments
to this registration statement (including post-effective amendments), and any other registration statements for the same offering pursuant to Rule 462(b) of the Securities Act of 1933, as
amended, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power
and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person,
hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant
to the requirements of the Securities Act, this registration statement has been signed by the following persons in the capacities and on the dates indicated.
|
|
|
|
|
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/ JOHN M. MASLOWSKI
John M. Maslowski
|
|
Director, President and Chief Executive Officer (Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)
|
|
November 6, 2017
|
/s/ DOUGLAS J. SWIRSKY
Douglas J. Swirsky
|
|
Chairman of the Board
|
|
November 6, 2017
|
/s/ KELVIN MOORE
Kelvin Moore
|
|
Director
|
|
November 6, 2017
|
/s/ MARC MAZUR
Marc Mazur
|
|
Director
|
|
November 6, 2017
|
II-9
Table of Contents
|
|
|
|
|
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/ JULIAN KIRK
Julian Kirk
|
|
Director
|
|
November 6, 2017
|
/s/ MARCUS SMITH
Marcus Smith
|
|
Director
|
|
November 6, 2017
|
/s/ CHRISTINE ST. CLARE
Christine St. Clare
|
|
Director
|
|
November 6, 2017
|
II-10
Fibrocell Science (NASDAQ:FCSC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Fibrocell Science (NASDAQ:FCSC)
Historical Stock Chart
From Jul 2023 to Jul 2024